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Abstract  
Background: Gestational diabetes mellitus (GDM) is defined as diabetes occurring or first 
recognized during pregnancy, and increases the risk of complications for both mother and the 
child during pregnancy, childbirth and beyond. Early detection is essential to prevent adverse 
outcomes associated with the condition and to reduce the increased risk of future diabetes 
type 2 in the women as well as the offspring. The STORK Groruddalen research program 
reported high prevalence of GDM in a multiethnic population of women attending Child 
Health Clinics (CHC) for antenatal care in Groruddalen, and large differences among the 
ethnic groups were observed. The current study aims to estimate the prevalence of GDM 
based on universal screening, which recently has been integrated as a part of the routine 
antenatal care in the same city districts, and to identify important risk factors for GDM.  
 
Methods: For the diagnosis of GDM, all women attending the CHC’s for routine care were 
invited to a 75 g oral glucose tolerance test between 24-34 weeks’ of gestation after an 
overnight fast. Venous plasma glucose was measured on site, and GDM was diagnosed using 
the World Health Organization criteria from 1999. BMI, body fat and vitamin D level were 
also measured, and questionnaire data on age, parity, family history of diabetes etc. were 
obtained. Multiple logistic regression analyses were performed to examine associations 
between GDM and potential risk factors. 
 
Results: The study sample consisted of 966 pregnant women (77% of invited), of whom 64% 
had ethnic minority background. Overall, 13.7% were found to have GDM, and there were 
large ethnic differences. The women from South Asia had the highest prevalence of 20.3%, 
followed by Middle East with 19.0%, both of which were significantly higher (p=0.001) than 
Western Europeans who were found to have a prevalence of 8.2%. Further, ethnic origin 
from South Asia and Middle East, first-degree relatives with diabetes, lower height and 
higher percentage body fat are risk factors associated with increased GDM risk. 
 
Conclusion: The prevalence of GDM found in these districts in Groruddalen is high and 
varies with ethic origin. Potential risk factors could help identify women with higher risk.  
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Sammendrag  
Bakgrunn: Svangerskapsdiabetes, definert som diabetes som oppstår eller først oppdages i 
svangerskapet, øker risikoen for uønskede komplikasjoner for både mor og barnet under 
svangerskapet, fødselen og senere i livet. Tidlig identifisering er svært viktig for å kunne 
redusere assosierte negative utfall samt den forhøyde risikoen for kvinnen og barnet til å 
utvikle diabetes type 2 i fremtiden. Forskningsprogrammet STORK Groruddalen fant høy 
forekomst av svangerskapsdiabetes blant kvinner som besøkte helsestasjonene i bydelene i 
Groruddalen, og store forskjeller ble observert mellom de etniske gruppene. Disse bydelene 
tilbyr nå screening av svangerskapsdiabetes som en integrert del av svangerskapsomsorgen. 
Hensikten med denne studien er å undersøke prevalensen samt identifisere risikofaktorer for 
svangerskapsdiabetes i de samme bydelene etter innføringen av dette nye tjenestetilbudet. 
 
Metode: Alle gravide kvinner som kom til helsestasjonen mellom svangerskapsuke 24 og 34, 
ble tilbudt en 2-timers 75 g glukosebelastning. Fastende og 2-timers verdi ble målt fra venøst 
blod, og svangerskapsdiabetes diagnostisert etter Verdens Helseorganisasjons kriterier fra 
1999. Videre ble BMI, fettprosent og vitamin D nivå målt, og det ble registrert opplysninger 
om blant annet alder, paritet og diabetes i familien. Logistisk regresjonsanalyser ble utført for 
å undersøke assosiasjoner mellom svangerskapsdiabetes og potensielle risiko faktorer.  
 
Resultater: Utvalget bestod av 966 gravide kvinner (77% av de inviterte), hvorav 64% hadde 
etnisk minoritetsbakgrunn. Av disse var det totalt 13.7% som hadde svangerskapsdiabetes, og 
prevalensen varierte sterkt med etnisk bakgrunn. Kvinner fra Sør-Asia hadde den høyeste 
prevalensen på 20.3%, etterfulgt av kvinner fra Midtøsten med 19.0%. Begge hadde 
statistisk signifikant høyere prevalens enn Norge med 8.2% (p=0.001). Videre var etnisk 
bakgrunn fra Sør Asia og Midtøsten, samt høyere fettprosent, lav høyde og diabetes i 
familien assosiert med høyere risiko for svangerskapsdiabetes.  
 
Konklusjon: Funnene i studien tyder på en høy forekomst av svangerskapsdiabetes i disse 
bydelene i Groruddalen, og prevalensen varierer sterkt med etnisk bakgrunn. Potensielle  
risikofaktorer kan identifisere kvinner med høyere risiko.  
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1 Introduction  
The burden of chronic diseases such as obesity and type 2 diabetes mellitus (T2DM) is rapidly 
increasing worldwide (Darnton-Hill, Nishida, & James, 2004). Changes in diets and lifestyles 
resulting from industrialization, urbanization and economic development have accelerated during 
the last decades and have significant impact on the health status of populations all around the 
world. Improved standards of living consisting of easy access to energy-dense foods along with a 
decline in the demands of physical activity both lead to negative consequences in terms of 
inappropriate dietary patterns and a more sedentary lifestyle (Nishida, Shetty, & Uauy, 2004). 
These trends are worrying not only because such conditions affect a large proportion of the 
population, but also because they have started to appear earlier in life (Darnton-Hill et al., 2004). 
 
Along with the rising tide of the current global epidemic of diabetes, an increase in gestational 
diabetes mellitus (GDM) is also observed (Ferrara, 2007). GDM is defined as diabetes occurring 
or first recognized during pregnancy, and is especially of concern as it increases the risk of 
complications for both mother and the child during pregnancy, childbirth and beyond (Buckley et 
al., 2012). Around 50% of women with GDM are expected to develop T2DM within 5 years after 
delivery (Kim, Newton, & Knopp, 2002). Their offspring are also at increased risk of developing 
obesity, impaired glucose tolerance, and diabetes as children or young adults, compared to those 
not exposed to maternal diabetes during fetal life (Ferrara, 2007).  
 
In Norway, as well as in the rest of Europe, the number of immigrants from Asia, Africa and 
South America has been rapidly increasing. As per 1 January 2014, the foreign-born population 
accounted for 14.9% of the total population in Norway. In some Eastern parts of Oslo, such as 
Groruddalen, immigrants from non-Western countries have reached >44% of the whole 
population (Statics Norway, 2014). This part of Oslo has since long been perceived as an area 
with low socioeconomic status, and shown to have markedly lower work participation rates, mean 
income as well as education, and the rates of people on social benefits are higher in Groruddalen 
compared to most other districts of Oslo (Thorsnæs & Gundersen, 2008). There are also marked 
differences in health between those on top and those on the bottom of the social hierarchy, and as 
in the rest of Europe, the social gap in Norway is not decreasing (Jenum, Stensvold, & Thelle, 
2001; Marmot et al., 2012). 
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Several immigrant groups are shown to have higher prevalence of poor health outcomes than the 
majority of the population, including musculoskeletal problems, vitamin D deficiency, anemia, 
and stomach cancer (Abebe, 2010; Hjern, 2012). Ethnic differences are also observed in the 
prevalence of obesity, T2DM and GDM (Hedderson, Darbinian, & Ferrara, 2010). In Europe, a 
high prevalence of diabetes has repeatedly been found in South Asians (Bhopal et al., 1999) 
Caribbean’s and other groups with ancestral origin from Africa (Davey Smith, Chaturvedi, 
Harding, Nazroo, & Williams, 2000) as well as in people with Middle Eastern, Turkish and 
Moroccan origin (Uitewaal, Manna, Bruijnzeels, Hoes, & Thomas, 2004). This indicates that 
ethnic minorities are disproportionally more affected by T2DM and GDM than the host 
population. In Groruddalen, Jenum, Holme, Graff-Iversen, and Birkeland (2005) found an 
alarmingly high prevalence of diabetes, especially in South Asian women (27.5% versus 2.9% in 
Norwegians). They also found that the majority of middle-aged non-Western women were 
physically inactive and obese. In addition, migrant populations have been shown to have a higher 
prevalence of T2DM compared to the prevalence in their native countries (A. Misra & Ganda, 
2007; Zargar et al., 2004), indicating that environmental factors may have an important role 
(Hedderson et al., 2010). 
 
The growing segment of the Norwegian population represented by recent immigrants may 
influence the proportion of women diagnosed with GDM and ultimately type 2 diabetes. This is a 
critical public health concern as GDM might reflect or contribute to the current patterns of 
increasing diabetes and obesity (Ferrara, 2007). Coordinated efforts along with additional 
resources are required by the health care system to provide care during pregnancy and to reduce 
adverse perinatal outcomes. Increased knowledge regarding the epidemiology of this condition is 
important as it may lead to new approaches to alter the trends in GDM and to prevent chronic 
diabetes in women and their offspring.  
 
1.1 STORK Groruddalen 
In light of this growing public health concern and as a response to the “National strategy to reduce 
social inequalities in health” launched in 2007, a research program was initiated in 2008 in which 
pregnant women and their offspring were targeted. Its main purpose was to increase the 
knowledge about GDM in a multiethnic population and establish better methods for identification 
of high-risk pregnancies. To this end, it was carried out in the residential areas of Groruddalen, 
Oslo, and the study program was given the name STORK Groruddalen (STORK). The ultimate 
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goal of this population-based cohort study was to reduce complications and long-term health risks 
for the mother and the offspring, and to develop and implement health promotion strategies 
related to care during pregnancy and infancy at the local level (Jenum et al., 2010). 
 
Women were recruited at the Child Health Clinics (CHC) in three chosen administrative city 
districts: Bjerke, Grorud and Stovner. In total, 823 pregnant women attending the CHC’s for 
antenatal care were included, and data from questionnaires, physical examinations, urine samples, 
vitamin D, oral glucose tolerance test (OGTT) and much more were collected during three visits 
(Jenum et al., 2010). Paternal questionnaire data were also collected. Two of the visits were 
during pregnancy, and one visit was three months post-partum. The women were tested for GDM 
at 28 weeks of gestation, e.g. the second visit.  
 
The study found a surprisingly high prevalence of GDM; 13.0% overall, with large differences 
among the ethnic groups (Jenum et al., 2012). As a result of the high prevalence rates reported, the 
three CHC’s continued to offer screening for GDM as a part of the antenatal routine program after 
the study completion. The measurement of the women’s vitamin D status was also continued, as 
the majority of women (80%) from the ethnic minority groups were vitamin D-deficient (Jenum, 
2010). The Norwegian Directorate of Health contributed and partly funded the strengthened 
antenatal care in these districts.  
Universal screening with an OGTT as part of the standard routine care is, as far as we know, 
offered only at these CHC’s (Bjerke, Grorud and Stover), in Groruddalen, as the current national 
guidelines recommend selective screening based on risk factors (Directorate for Health and Social 
Affairs, 2009). This is the first time in Norway all pregnant women are given equal possibility to 
be identified with GDM by being routinely tested in the antenatal care.  
The high rates of this disorder found in the STORK Groruddalen study have been questioned, 
making it especially important to validate these findings in another larger sample. Additionally, it 
has led to a strengthening of the antenatal care in these districts, with implications such as 
increased local workload and health care costs. It is therefore an urgent need to compare 
prevalence rates reported with results from a new study from routine care, with the goal to ensure 
that such structural changes are necessary and beneficial.  
 
The present study aims to determine the ethnic differences in the prevalence of GDM assessed as 
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part of the routine at the CHC's. The screening is optional; however, most women choose to 
perform it according to the CHC staff. Moreover, more women are likely to participate as 
screening is offered as a routine. This will allow for a better representativeness and potential 
selection bias occurring in STORK-Groruddalen could be reduced. The current study opens a 
unique window to explore prevalence rates and risk factors outside a research setting. 
Furthermore, a high prevalence of GDM may indicate a need to implement universal screening in 
the antenatal care in Norway.  
 
The next chapter of this thesis will present the aims and the theoretical background of the study. 
Chapter 4 describes the methods applied, the data collection process as well as the statistical 
analyses. Next, the results will be presented and discussed in light of previous research in the 
field. The last chapter is a conclusion and summary of the main findings in this study.  
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2 Aims & Research questions 
Main objective 
! Measure and compare the prevalence rates and risk factors of GDM in different ethnic 
groups 
 
Secondary objective 
! Compare the prevalence rates in this study from routine care with results from STORK-
Groruddalen collected in a research setting 
 
The main research questions are: 
What is the prevalence of women with GDM in the largest ethnic minority groups compared 
to Western Europeans? 
What are the risk factors found to be associated with GDM? 
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3 Background 
 
3.1 Gestational diabetes mellitus 
3.1.1  The definition  
Gestational diabetes mellitus is defined as any degree of glucose intolerance with onset, or first 
recognition during pregnancy (Buchanan, Xiang, Kjos, & Watanabe, 2007; Metzger et al., 2007). 
The definition acknowledges the possibility that patients may have undiagnosed diabetes prior to 
the pregnancy, or hyperglycemia induced by the pregnancy. Usually the blood glucose levels 
normalize and symptoms subside after birth, but this is not a prerequisite in the definition (Landon 
& Gabbe, 2011). 
 
3.1.2 Metabolic adaptations during normal pregnancy and GDM  
Throughout a normal pregnancy, a series of complex metabolic changes occur to ensure an 
adequate and continuous supply of nutrients to the growing fetus (Butte, 2000). The pregnancy 
state can be viewed as a diabetogenic and inflammatory state in which the glucose and lipid 
metabolism are altered resulting in higher levels of maternal fat deposition, hyperlipidemia and 
insulin resistance (Bilhartz, Bilhartz, Bilhartz, & Bilhartz, 2011).  
 
Insulin, which is a hormone produced by pancreatic β-cells, enables the cells to increase the 
glucose uptake from blood, and use it as fuel or convert it to glycogen in liver and muscles. 
Insulin resistance is a decreased biological response to a given concentration of insulin at the 
target tissue, e.g. liver, muscle or adipose tissue (Catalano, 2010). In pregnancy, the resistance to 
insulin, beginning near mid-pregnancy and progressing through the third semester (Buchanan & 
Xiang, 2005) increases about 50-60% (Catalano, 2010). This may result from a combination of 
increased maternal adiposity and hormones secreted by the placenta. In healthy women, the 
pancreatic β-cells increase their insulin secretion as a response to the pregnancy induced insulin 
resistance in order to keep blood glucose levels in the normal range. In other words, the balance 
between insulin resistance and insulin supply is maintained, resulting in rather small changes in 
circulating glucose levels over the course of pregnancy compared with the large changes in insulin 
sensitivity (Buchanan et al., 2007). 
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In the pathophysiology of GDM, inadequate insulin secretion to compensate for the insulin 
resistance is caused by pancreatic β-cell dysfunction and plays a central role (Metzger et al., 
2007). To maintain stable blood glucose levels over the course of pregnancy, robust plasticity of 
β-cell function is necessary (Buchanan et al., 2007). Many underlying causes of such a β-cell 
dysfunction have been suggested, however, a chronic insulin resistance represents the majority of 
cases (Buchanan, Xiang, & Page, 2012). Women who develop GDM are thought to have a 
reduced capacity to adapt to the increased insulin resistance, leading to maternal hyperglycemia.  
 
3.1.3 Adverse outcomes 
The presence of GDM has important consequences and increases the risk of complications for 
both mother and child during pregnancy, childbirth and beyond (Buckley et al., 2012). Lesser 
degrees of glucose intolerance have also been shown to be harmful (Yogev et al., 2010), and the 
immediate and long-term clinical sequelae are significant contributors to the burden of disease in 
many countries (Jiwani et al., 2012). The following section will describe adverse maternal and 
fetal outcomes associated with GDM.  
 
3.1.3.1 Offspring  
Excessive fetal growth remains an important perinatal concern in GDM. The placenta is the 
primary interface between the mother and her child. As maternal glucose can freely pass the 
placenta, increased glucose concentrations on the maternal side will result in increased glucose 
fluxes from mother to fetus (Metzger et al., 2007). Compensating for the excessive glucose 
transfer, the fetus has to increase the secretion of insulin to the same extend, leading to fetal 
hyperinsulinemia. This might in turn lead to increased growth and adiposity, as insulin is a growth 
hormone (Pedersen, 1971). Macrosomia, characterized by disproportionately increased fetal 
growth, occur more frequently in infants of women with GDM than their healthy counterparts.  
 
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study was conducted to clarify 
unanswered questions on the association between maternal glycaemia and the risk of adverse 
pregnancy outcomes. This large study, carried out in 15 centers in nine countries, showed that 
there was a continuous relationship between maternal blood glucose levels following a 75g 
glucose load (fasting, 1-hour and 2-hours) and the primary outcomes; above 90-percentile for 
birth weight and cord C-peptide, clinically neonatal hypoglycemia and caesarean section, and the 
secondary outcomes; preterm delivery, shoulder dystocia/birth injury, hyperbilirubinemia and 
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need for intensive neonatal care (Hapo Study Cooperative Research Group et al., 2008). 
Numerous studies are consistent with the results from the HAPO study, showing a relationship 
between higher maternal glucose and increasing frequency of adverse perinatal outcomes (Jensen 
et al., 2008; Pettitt, Knowler, Baird, & Bennett, 1980; Sermer et al., 1995).  
 
There are also a number of studies relating maternal glycaemia to long-term consequences in the 
offspring (Pettitt & Knowler, 1998); however, these effects are less clear and well-described than 
the immediate effect on fetal growth. Consequences of a hyperglycemic or hyper-nutritional 
uterine environment are suggested include an increased vulnerability to develop obesity and 
diabetes in adult life (Dabelea & Crume, 2011; Kelstrup et al., 2013). A recent analysis of the 
HAPO study, however, did not find a relationship between maternal glucose levels and child 
obeisty at 2 years age (Pettitt et al., 2010).  
 
3.1.3.2 Maternal 
The majority of women with GDM will return to normal glucose tolerance immediately after 
delivery; however, a significant number will remain diabetic or continue to have impaired glucose 
tolerance (Metzger et al., 2007). GDM can therefore be considered an early marker of 
disturbances in the glucose metabolism, and more than a disease (Buchanan et al., 2012), can be 
viewed as a risk factor for type 2-diabetes (Landon & Gabbe, 2011). Women with a previous 
GDM history are shown to have a 7-fold risk of future type 2 diabetes, compared with their 
normal non-diabetic counterparts (Bellamy, Casas, Hingorani, & Williams, 2009). It is estimated 
that about 10% of the women with GDM develop type 2 diabetes within four years, and up to 60% 
ten years postpartum (Buchanan et al., 2012).  
 
The HAPO study (Hapo Study Cooperative Research Group et al., 2008) suggested a relationship 
between maternal glycaemia and preeclampsia, which is defined as hypertension and proteinuria 
that develops during pregnancy (Bilhartz et al., 2011). Also, as women with a history of GDM 
have been found to have higher values of markers of endothelial dysfunction, as well as increased 
intimal medical thickness of the carotid arteries compared to healthy women (Bo et al., 2007), 
GDM has been recognized as a risk factor for future cardiovascular disease (Bilhartz et al., 2011; 
Kessous, Shoham-Vardi, Pariente, Sherf, & Sheiner, 2013).  
 
Fetal macrosomia is in addition associated with increased risk of difficult delivery and maternal 
damage, and this is confirmed in large populations (Boulet, Alexander, Salihu, & Pass, 2003; 
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Esakoff, Cheng, Sparks, & Caughey, 2009). Furthermore, the consequences of excessive fetal 
growth include birth trauma and maternal morbidity from operative delivery. The cesarean 
delivery rate is also increased in patients with GDM, in part to avoid birth trauma (Metzger et al., 
2007). 
  
3.1.4 Diagnostic criteria  
It has been proposed a large number of procedures and glucose cut-off values for the diagnosis of 
glucose intolerance in pregnancy over the time (World Health Organization [WHO], 2013). The 
first GDM criteria were established in the 1960’s by O’Sullivan and Mahan, who found that the 
degree of glucose intolerance during pregnancy was related to the risk of developing diabetes after 
pregnancy (Buchanan & Xiang, 2005). By investigating the distribution of plasma glucose values 
of pregnant women, they proposed diagnostic criteria for gestational diabetes based on a 3-h 100 g 
OGTT. Later they validated these criteria against the development of future diabetes in the mother 
(WHO, 2013). GDM was diagnosed if two or more blood glucose values were ≥2 standard 
deviations above the population mean.  
 
In the 1980’s, the National Diabetes Data Group (NDDG) adapted these cut-off points to newer 
methods for measuring glucose due to advanced laboratory technics, and applied them to the 
definition of gestational diabetes (Buchanan & Xiang, 2005). The American Diabetes Association 
and many other associations accepted the NDDG recommendation and these criteria, with 
modifications, remain in use today, mainly in the US. The World Health Organization’s 
recommendation from 1999 is based on a 2-h 75g OGTT and applies the same diagnostic criteria 
for GDM as for diabetes and impaired glucose tolerance for non-pregnant adults. These criteria 
are used in Norway along with other European and developing countries. None of these diagnostic 
criteria are directly based on perinatal outcomes, and rather focus on the women’s risk of 
developing diabetes after pregnancy (Paglia & Coustan, 2011).   
 
The International Association of the Diabetes and Pregnancy Study Group (IADPSG) was formed 
in 1998 to facilitate an international approach to enhancing the scientific understanding, diagnosis 
and management of diabetes in pregnancy (International Association of et al., 2010). Recently, the 
multinational HAPO study demonstrated a continuum of risk for maternal glycaemia and adverse 
pregnancy outcomes (Hapo Study Cooperative Research Group et al., 2008), leading to the 
IADPSG proposing a new set of guidelines for GDM. This recommendation was based on the 
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fasting 2-h 75 g OGTT used in the HAPO study to standardize the glucose load internationally, 
and said that all women not previously diagnosed with diabetes should be evaluated at 24-28 
weeks’ of gestation. Specific cut-offs were set above which women would be diagnosed with 
GDM, reflecting an odds ratio [OR] of at least 1.75 for birth weight, cord C-peptide or percentage 
body fat greater than the 90th percentile, compared to neonates of women with glucose values 
below the mean (International Association of et al., 2010).  
 
In light of new data and considering the fact that the diagnostic criteria from 1999 are over ten 
years old and not evidence-based, the WHO also updated their recommendations for 
hyperglycemia in pregnancy in 2013, endorsing the criteria proposed by IADPSG (WHO, 2013). 
These new criteria and the WHO 1990 criteria, which are still in use in Norway, are presented in 
table 1.  
 
Table 1 Threshold values for diagnosis of GDM, with a 75-g glucose challenge. Values in mmol/l.  
Definition  Fasting PG 1-h PG 2-h PG 
WHO 1999  
IAPDSG/ WHO 2013 
7.0 
5.1 
 
10.0 
7.8 
8.5 
* At least one of the venous plasma glucose (PG) values must be met or exceeded for the diagnosis of GDM. 
 
 
3.1.5 Screening 
For the diagnosis of GDM, an OGTT, preferably between 24 and 28 weeks, is needed. 
Nevertheless, routine screening for GDM and the most effective approach for the systematic 
detection of this disorder remain controversial topics (Buckley et al., 2012). Different protocols 
are in use internationally and there are different recommendations regarding which pregnant 
women should be selected for biochemical testing, how the test should be performed and what 
glycaemic threshold should be considered diagnostic (Walker, 2008). Also, screening practices 
are inconsistent across Europe and even within countries. Some recommend systematic screening 
of all pregnant women while others test on a case- by-case basis according to established risk 
factors and clinician or patient decisions (Buckley et al., 2012).  
 
The WHO and IADPSG both recommend the 75-g OGTT. IADPSG guidelines recommend 
screening all or high-risk women at the initial visit, whereas the WHO has not stated any guidance 
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as to which women should undergo the OGTT. In North America, screening has commonly 
involved a two-step approach for all women; a non-fasting 1-hour 50 g glucose challenge test at 
the first antenatal visit (Berger & Sermer, 2009; Vandorsten et al., 2013), and those with abnormal 
glucose values proceed to the second step, which is to undergo either a 100-g or a 75-g OGTT for 
the diagnosis of GDM (Buchanan et al., 2012).  
 
In Norway, screening for GDM using risk factors is recommended in a healthy population. The 
Directorate for Health and Social Affairs (2009) recommended the 2-hour 75 g OGTT for women 
with: Morning glycosuria; Age > 38 years; First degree relatives with diabetes; BMI > 27 kg/m2; 
A history of GDM or an ethnic origin from a country outside Europe with high diabetes 
prevalence.  
 
3.1.6 Prevalence 
Estimating the prevalence of gestational diabetes is made difficult by a lack of universally 
accepted diagnostic criteria, as well as variation in screening procedures, differences in sample 
population and methodologies used (Reece, Leguizamon, & Wiznitzer, 2009). As a result, it has 
been difficult to compare the prevalence of GDM among ethnic groups or to determine whether 
GDM rates have changed over time (Buckley et al., 2012).  
 
The reported prevalence of GDM varies from 1 to 20%, and ethnic differences in the prevalence 
most certainly exist (Buckley et al., 2012; Jiwani et al., 2012; Lamberg, Raitanen, Rissanen, & 
Luoto, 2012; Schneider, Bock, Wetzel, Maul, & Loerbroks, 2012). In the US, Asians, Hispanics 
and African-American women have been reported to be at a higher risk of GDM than non-
Hispanic white women (Ferrara, Hedderson, Quesenberry, & Selby, 2002; Ferrara, Kahn, 
Quesenberry, Riley, & Hedderson, 2004; Thorpe et al., 2005). Similarly, a study from Australia 
showed higher prevalence among women born in China or India compared to women whose 
country of birth was in Europe or Northern Africa (Beischer, Oats, Henry, Sheedy, & Walstab, 
1991). Likewise in Europe, GDM is found to be more common among Asian women than 
Europeans (Dornhorst et al., 1992). Noteworthy, the proportion of women with GDM is lower in 
Asian countries when compared to the proportion observed in Asian women living in other 
continents (Yang et al., 2002). In India, it was observed that GDM was more common in women 
living in urban areas than in women living in rural areas (Zargar et al., 2004). A large study 
reviewing European evidence relating to the prevalence of GDM reported a trend where lower 
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prevalence in Northern or Atlantic seaboard part of Europe predominates, while higher estimates 
have been detected in the South and Mediterranean seaboard regions (Buckley et al., 2012).  
 
In Norway, the prevalence of GDM in the total population is not documented, however, a few 
studies report a rate of 6-7% among selected groups of ethnic Norwegian women (Froslie et al., 
2013; Voldner et al., 2008). The STORK Groruddalen study recently reported an overall 
prevalence of 13.0% (with the 1999 WHO-criteria) where several ethnic groups, such as South 
Asians and Middle Easterners, were found to have a higher prevalence (14.8 and 16.9%, 
respectively) compared with Western Europeans (10.8%) (Jenum et al., 2012).  
 
The rate of GDM is rising worldwide in line with increasing trends of maternal obesity and type 2 
diabetes (Finucane et al., 2011; Wijesuriya, Williams, & Yajnik, 2010). Moreover, the prevalence 
of GDM usually reflects the underlying prevalence of type 2 diabetes in the population studied 
(Ferrara, 2007; Moses & Cheung, 2009). Middle East and South Asia are found to have the 
highest increase in the prevalence of diabetes (Chan et al., 2009), and rates are higher for ethnic 
minority groups living in western countries compared with the host population (Hu, 2011; Jenum 
et al., 2005; Wandell, Carlsson, & Steiner, 2010). 
 
3.1.7 Risk factors 
As GDM and T2DM share pathophysiological similarities (Barbour et al., 2007; Buchanan et al., 
2012) and have the same genetic susceptibility, risk factors similarities also exist between the two 
disorders (Ben-Haroush, Yogev, & Hod, 2004). Several risk factors for gestational diabetes 
mellitus are well known and discussed in the literature. Among these are advanced maternal age, 
obesity, prior GDM history and family history of diabetes (Dode & dos Santos, 2009). For other 
risk factors, such as parity, race or ethnicity, physical activity and socioeconomic factors, some 
inconsistency between studies exists. It is highly significant to identify these risk factors, in 
particular the modifiable ones, to be able to prevent GDM among high-risk populations.  
 
Among the well-recognized modifiable risk factors, excessive adiposity is the most commonly 
investigated with consistent findings (Chu et al., 2007). Obesity induces insulin resistance and 
chronic B-cell dysfunction (Buchanan et al., 2007), and a meta-analysis concluded that the risk for 
GDM increases substantially and progressively in overweight, obese and morbidly obese women 
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(Chu et al., 2007). It is, however, important to note that the majority of obese subjects maintain 
normal glucose tolerance (Abdul-Ghani, Lyssenko, Tuomi, DeFronzo, & Groop, 2009). 
 
Available data suggest that health behaviors like dietary habits and physical activity influence the 
development of GDM (Oostdam, van Poppel, Wouters, & van Mechelen, 2011; Zhang & Ning, 
2011). Some studies indicate that physical activity right before and during pregnancy could 
modify the risk (Dode & dos Santos, 2009). Epidemiologic studies on the role of dietary factors 
for GDM are at their early stage, and even though a low glycaemic index diet might be beneficial, 
conclusions cannot be drawn regarding diet (Oostdam et al., 2011; Zhang & Ning, 2011). 
 
It has been observed that some racial and ethnic groups have higher frequencies of GDM, leading 
to a number of studies evaluating the role of racial factors (Dode & dos Santos, 2009). Ethnicity 
may be defined as the social group a person belongs to, which implies shared culture, history, 
geographical origins, language, diet, physical, genetic and other factors (Bhopal, 2004). Being 
member of an ethnic group with high prevalence of diabetes, generally including Hispanic, Native 
American, South and East Asian, black Caribbean and those of Pacific Islands ancestry and 
Middle Eastern descent (American Diabetes, 2012; Hedderson et al., 2010) is suggested as a risk 
factor.  
 
Dode and dos Santos (2009) noted that high prevalence of GDM was found among ethnic groups 
in studies carried out with populations of immigrants in Western countries. However, the 
prevalence is lower in studies made in the original countries of these populations. This indicates 
that factors associated to the immigrant situation or to socioeconomic conditions might play a 
role. In the US and other countries as well, most ethnic minorities are more likely to be poorer and 
less educated than the white population. It has therefore been discussed whether the high 
prevalence of diabetes is attributable to ethnicity or if it is due to socioeconomic status (Link & 
McKinlay, 2009).  
 
Socioeconomic position (SEP), referring to the socially derived economic factors that influence 
what position individuals or groups hold within the multiple-stratified structure of a society  
(Galobardes, Lynch, & Smith, 2007; Krieger, Williams, & Moss, 1997), is shown to influence 
health outcomes over the life course. Poorer socioeconomic circumstances may lead to poorer 
health by operating through several complex mechanisms like stress and underuse of health 
services, resulting in an unequal distribution of some conditions across socioeconomic groups 
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(Brown et al., 2004; Galobardes et al., 2007; D. P. Misra & Grason, 2006). For instance, subjects 
with poor SEP are reported to have inadequate health behavior, and a higher risk for T2DM 
(Agardh, Allebeck, Hallqvist, Moradi, & Sidorchuk, 2011; Evenson & Wen, 2010; Stringhini et 
al., 2012). Likewise, an inverse association between GDM and socioeconomic level has been 
found in some studies, where level of education in particular is inversely associated with GDM 
after adjustment for other socioeconomic and demographic variables (Innes et al., 2002). 
Nevertheless, the association between SEP and GDM has not been comprehensively studied and it 
is not clear if socioeconomic level can be viewed as a risk factor (Anna, van der Ploeg, Cheung, 
Huxley, & Bauman, 2008; Cullinan et al., 2012; Dode & dos Santos, 2009).   
 
Increasing observational and experimental evidence show that growth and development during 
fetal and early life have an important role for health later in life (Gluckman, Hanson, Cooper, & 
Thornburg, 2008; Godfrey, 1998; Lehnen, Zechner, & Haaf, 2013). Mother’s diet, body 
composition and health determine the intrauterine environment (Hanson & Gluckman, 2011), in 
which the human fetus is growing and able to adapt. If the adaptation is permanent, it is 
considered as a “programming” change with persistent effects in structure, function and 
metabolism (Wadhwa, Buss, Entringer, & Swanson, 2009). Some of these offspring programmed 
to survive undernutrition continue to be malnourished and stunted during childhood. The 
programming is often beneficial in the short run, and as long as they have the same lifestyle as in 
the early life, they remain at a relatively low risk for non-communicable diseases later in life 
(Veeraswamy, Vijayam, Gupta, & Kapur, 2012). However, it might be detrimental if there is a 
“mismatch” between the offspring’s predicted living environment and actual living environment 
(Hanson & Gluckman, 2011), which can be changed by migrating to urban areas as adult and lead 
to changes in the macro environment for which they were not programmed (Ramachandran et al., 
2004; Snehalatha & Ramachandran, 2009). Such changes in life circumstances increase the risk 
for adverse health outcomes, and subjects that grow up in affluent societies are found to be at 
higher risk of hypertension, T2DM and cardiovascular disease at much lower birth weight, BMI 
and central adiposity threshold (Pilgaard et al., 2010). These effects may in young women present 
first during pregnancy, resulting in GDM (Seshiah, Balaji, Balaji, Paneerselvam, & Kapur, 2009). 
Several studies report associations between GDM and low birth weight, as well as GDM and short 
adult stature (stunting) (Ogonowski & Miazgowski, 2010). 
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3.1.8 Treatment and effect 
A number of studies indicate that early detection and management of GDM improves outcomes 
for both mother and child (Crowther et al., 2005; Landon et al., 2009; Reece et al., 2009; Sacks, 
2009). Initial treatment is aimed at lowering blood glucose concentrations and involves changes in 
diet, moderate exercise and glucose self-monitoring. The majority of women will benefit from 
antenatal management of GDM consisting of such lifestyle modifications (Falavigna et al., 2012; 
Petry, 2010). However, these figures depend on the population studied, methods applied and 
content of the intervention (Falavigna et al., 2012). There are several options available for 
intensifying therapy beyond lifestyle modifications as well. When dietary management does not 
achieve desired glucose control, insulin and oral antidiabetic medications may be used (Hartling et 
al., 2013).  
 
Two large randomized controlled trials have shown significant reduction in perinatal 
complications with these strategies, compared to women with GDM receiving routine prenatal 
care alone (Crowther et al., 2005; Landon et al., 2009). These studies found that treatment results 
in lower incidence of macrosomia, large-for-gestational-age, shoulder dystocia and preeclampsia 
in pregnancy. However, the effect on childhood obesity was less convincing even though there 
were fewer “big babies” at birth (Gillman et al., 2010; Pettitt et al., 2010). Moreover, current 
research does not show a treatment effect of GDM on future poor metabolic outcomes of the 
offspring (Hartling et al., 2013).  
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4 Material and methods  
Systematic observation and testing can be accomplished using a wide variety of methods, 
however, two general approaches are widely recognized: qualitative research or quantitative 
research. The selection of scientific method depends primarily on the research questions being 
asked and the type of data being collected (Johannessen, Tufte, & Kristoffersen, 2010). Aliga and 
Gundersen (as cited in Muijs, 2011, p. 1) describe quantitative research as: “…Explaining 
phenomena by collecting numerical data that are analyzed using mathematically based methods 
(in particular statistics)”. By contrast, qualitative research is a subjective approach used to 
describe life experiences and give them meaning, and is not usually numerical (Johannessen et al., 
2010). For this study a quantitative approach is found to be most appropriate and its selection is 
based upon the problem of interest e.g. assessing the prevalence rates of a condition, which 
requires data being collected in numerical form.   
 
4.1 Study design 
A cross-sectional study aims at determining the frequency of a particular attribute, such as a 
disease, specific health outcomes or any other health-related event, in a given population at a 
particular point in time (Levin, 2006). Data can be collected on individual characteristics, 
including exposure to risk factors, alongside information about the outcome. 
 
This study entails the collection of data on a cross-section of the population, comprising a 
proportion of it, e.g. all women attending the Child Health Clinics in Groruddalen, Oslo, for 
antenatal care. It is descriptive in nature, providing a prevalence rate at a particular point in time, 
as well as assessing the factors providing the outcome (Frigessi, Moger, Scheel, Skovlund, & 
Veierod, 2006). Moreover, the study can be considered population-based, implying sampling of 
individuals from a geographically defined general population (Szklo, 1998).  
 
Prevalence and incidence are two closely related terms, and both estimates are reported in the 
literature regarding GDM, often used interchangeably (Golden et al., 2012). In this study, 
prevalence, defined as the proportion of a population found to have a condition at a given point in 
time, is chosen over incidence, which is a measure of new cases arising in the study population 
during a defined period of time (Rothman, 2012). According to Mosdol and Brunner (2005) 
prevalence is often used to estimate the disease burden in a population, for instance to plan health 
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services. As GDM is assessed at a given point in time in a woman’s pregnancy, the term 
prevalence was found to be most appropriate. 
 
4.2 Setting 
The study invited all women attending the Child Health Clinics in Groruddalen, Oslo (Stovner, 
Grorud, and Bjerke administrative city districts) for antenatal care. These districts cover a 
population of 87,257 and reflect diverse ethnical backgrounds. The proportion with ethnic 
minority origin in Stovner, Grorud and Bjerke was 42.8%, 36.0% and 29.7%, respectively, in 
2014 (Statics Norway, 2014).  
Antenatal care is a routine part of pregnancy, provided free of cost to all women living in the 
districts to monitor the mother and baby’s health. This care can be delivered in primary, secondary 
or community setting, and the women have the option of visiting midwifes at the CHC’S, the 
general practitioner (GP) or a combination of both. For healthy normal women, a schedule of 
eight routine appointments is regarded adequate, offered from the first trimester up to gestational 
week 40. Ultrasound examination is also performed in one of these appointments to determine the 
date of term, usually around 17-20 weeks’ of gestation.  
The CHC’s in Stovner, Bjerke and Grorud offer one additional antenatal appointment at 
gestational week 28± for screening. Patients are screened for GDM by undergoing a 2-h 75 g oral 
glucose tolerance test. When receiving the standard information about the antenatal care, all 
women are given information about this test and requested to come in the fasting state. 
Information letters developed in the STORK Groruddalen study program, available in 8 different 
languages, are used for this purpose. Furthermore, patients are informed about STORK 
Groruddalen and the high prevalence of GDM found for all ethnic groups in the study. The 
benefits of screening are highlighted as well as the fact that results will be known to the women 
immediately after the test. Information based on routinely recorded data from these appointments, 
collected and provided by staff at these CHC’S, will be presented in the following chapters.  
 
4.3 Study population 
The population of interest for a particular study question is called the population at risk or the 
target population (Mosdol & Brunner, 2005). In this study, all pregnant women living in these 
districts constitute the target population. The data collection period lasted from March 2011 to 
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December 2012; however, Bjerke city district started the screening a year after the other two so 
that the inclusion period lasted for one year only (2012) for this CHC. According to data 
monitoring the activity at the CHC’s, mainly based on the number of newborns in the districts, it 
is estimated that approximately 70-80% attend the CHC’s during their pregnancy.  
 
During the inclusion period, a total of 1561 pregnant women visited the three CHC’s for antenatal 
care. The numbers of invited, included and excluded subjects are presented in a flowchart (figure 
1). A number of women were not offered the screening either because of attendance at the CHC 
late in their pregnancy or due to logistic and administrative challenges at the CHC’s (holidays, 
sick leave etc.). Of those invited, some choose to perform screening at their GP’s or have already 
undergone it, while a few did not wish to be tested. Other reasons include moving out of the area 
or not being able to make it to the scheduled appointment due to holidays etc. Our best estimate 
based on routine monitoring data and information from the staff at the CHC’s indicates that 1313 
subjects were eligible and invited. As 1018 women accepted the invitation to perform screening 
we have estimated that at least 77% of the eligible women accepted the invitation to be screened 
for GDM.  
 
Further, to be included in the analyses of this study, the OGTT had to be performed between 24 
and 34 weeks’ of gestation, unless diagnosed with GDM at an earlier point in the pregnancy, as 
some women (n=4) were tested earlier due to known risk for GDM before 24 weeks’ (GDM in 
previous pregnancies etc.). The main reason for exclusion was gestational week e.g. too early or 
late attendance (n=26). 
 
Other reasons for being excluded were not being able to complete the OGTT due to hyperemesis 
and difficulties drinking the glucose mix. Women experiencing vomiting before one hour after 
drinking the glucose were excluded due to presumably invalid test results (n=16), while cases of 
vomiting occurring after one hour have been included (n=8). Some had problems drawing blood 
and were excluded for this reason (n=2). Five women were not tested as they did not meet fasting, 
and two were unable to perform the OGTT due to hyperemesis. Three women were not given 
glucose because of high fasting plasma glucose (FPG) and referred to their GP instead. Their 
fasting values have been included but the 2-h values are missing. The study sample consists of 966 
women, constituting 95% of those who accepted the invitation for screening with OGTT.  
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4.4 Data collection 
Data collection was entirely performed by the CHC staff. However, data was registered from the 
questionnaires by me, for which EpiData Entry was used - a software designed for simple or 
programmed data entry and data documentation.  
 
!
All!CHC!Women!!n=!1561!!
Not!invited,!n=248!!QLate!attendance!Q!Logistics!!
Accepted!to!be!screened!n=1018!(77%)!!
Not!screened,!n=295!Q!Refused!participation!Q!OGTT!at!GP’s!Q!Appointment!didn’t!suit!Q!Unknown!reasons!
Included!!n=!966!(95%)!
Excluded,!n=52!Q!Gestat.!week!<24!and!>34,!n=26!Q!Did!not!perform!OGTT,!n=7!Q!Could!not!complete!OGTT,!n=18!
Eligible!women!n=1313!
Figure 1 Attendance at the CHC from March 2011 to December 2012; those eligible, those who were not 
offered screening, those not screened and those who were excluded in this study by reasons for exclusion.   
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4.4.1 Description of the background variables 
A questionnaire is a written instrument used to obtain information from study subjects (World 
Health Organization, 2008). Demographic and historical information were obtained by trained 
midwifes, using a standardized interviewer-administrated questionnaire (appendix 1). In contrast 
to a self-administered approach where questionnaires are answered at by the respondents 
themselves (ibid.), the women in this study provided answers to the midwife who noted them on 
the questionnaire. The following is a description of the background information that the women 
were asked to self-report on. 
 
4.4.1.1 Demographics  
Age 
Upon arrival at the CHC’s, the date of the visit and the women’s date of birth were registered. 
These variables were used to calculate the age, a continuous variable. Age was later divided into 
three categories for use in certain analysis. The cut points for the categories were selected to have 
approximately the same proportion of subject in each age group. 
 
Ethnic origin 
In this study, ethnic origin was defined by the participant’s country of birth or the participant’s 
mother’s country of birth if she was born outside of Norway. Ethnic origin was self-reported by 
most women and was otherwise obtained from medical records. In cases where ethnic origin was 
lacking in both the questionnaires and medical records, the staffs at the CHC’s were contacted 
directly to request this missing information.  
 
The women’s country of origin was further categorized into ethnic origin groups (regions) 
commonly used in medical research (Danaei et al., 2011) and as previously applied in the STORK 
Groruddalen study (Jenum et al., 2010) prior to analysis. The categories were as following: 
Norway & other Western (including North America), South Asia, Middle East (including North 
Africa/Central Asia), Sub-Saharan Africa (except North Africa), Eastern Europe, East Asia and 
South America (including Central America).  
 
This variable was in addition recoded into “Norway & Other Western” and “Non-Western” 
(including all other groups), for one specific analysis to check for differences between the study 
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sample and excluded subjects. This was mainly done due to small sample size in most of the 
ethnic group in the excluded sample.  
 
4.4.1.2 Obstetric and medical information 
Gestational week at inclusion 
Women are offered a routine ultrasound examination in a previous appointment (between 
gestational week 17-20) from which estimation of the woman’s expected date of delivery is made. 
This date was noted on the questionnaire, and later used to determine the gestational age at 
OGTT. In case of missing expected date of delivery, the woman’s date of last menstrual period 
was used for this purpose. The following formula has been used to determine the gestational age 
at point of OGTT:  
 
Expected date of delivery – 282 = last date of menstrual period 
(Date of visit - last date of menstrual period)/7 = gestational age in weeks 
 
Parity 
If the woman had been pregnant previously, the number of live births was reported. Parity was 
defined as the number of previous pregnancies lasting more than 22 weeks. This was originally a 
continuous variable, which was later reclassified into nulliparous (no previous pregnancy), 
uniparous (one previous pregnancy) and multiparous (two or more previous pregnancies) for the 
analysis.  
 
Family history of diabetes 
The woman was asked to report if she had any first-degree relatives with diabetes. Family history 
of diabetes was defined as a history of type 2 diabetes, type 1 diabetes or unknown diabetes type 
in any family members, including parents, siblings or children. This variable was recoded into 
having first-degree relatives with known diabetes and having relatives without known diabetes.  
 
Previous history of GDM 
All women were asked whether they have had GDM in previous pregnancies, and this information 
was registered as a dichotomous variable with the responds ‘yes’ and ‘no’. This variable will be 
presented only for the uniparous and multiparous women (≥1 children).  
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4.4.2 Description of the physical measurements  
After responding to a number of questions related to the risk for GDM, the women went through a 
series of measurements and tests. Screening for gestational diabetes consists of the steps described 
in the next chapters.  
 
4.4.2.1 Blood samples 
The blood samples performed at the appointment consist of a 2-h OGTT and vitamin D test. 
 
Oral glucose tolerance test  
The oral glucose tolerance test measures the body's ability to use sugar (glucose), and is currently 
the gold standard for a definite diagnosis of GDM (Olabi & Bhopal, 2009).  
 
Venous blood samples are drawn after an overnight fast. The second blood sample will be 
collected 2 hours after drinking a sweet liquid containing a measured amount of glucose (75 
grams). Blood glucose was analyzed on site, within 5 min after vein puncture, in venous EDTA 
blood according to a standardized protocol, using a patient-near method (HemoCue 201+, 
Angelholm, Sweeden). This method is preferred to give immediate results to allow optimal patient 
information and necessary actions when GDM is diagnosed (Jenum et al., 2010). In addition, 
venous blood tests was transferred to gel glass and sent for further analysis to the Akershus 
University hospital. The three instruments were externally validated during STORK (Jenum, 
2010), and calibrated for plasma and with the same batch number for cuvettes and controls (run 
weekly). These procedures were followed after STORK as well.  
GDM was diagnosed according to the 1999 WHO-criteria (if one of two criteria was met: FPG ≥7 
or 2-h PG ≥7.8 mmol/l), and the results of the blood tests were made known to the mothers 
immediately after. Women with fasting values above 7 mmol/l, and 2-hour values of 7.8-8.9 
mmol/l were given lifestyle and dietary advice, along with written information on how to manage 
the condition. These leaflets were developed in STORK Groruddalen study program for 
distribution to women with GDM, and were available in 8 different languages. Furthermore, these 
patients were remitted to their general practitioner for follow-up.  
Those with fasting glucose >7.0 mmol/l or 2-hour values ≥9 mmol/l were referred to secondary 
care for follow-up. Letters with the laboratory results were sent to their general practitioners in 
addition.   
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The results, both the local values and laboratory values, were recorded in the questionnaire forms. 
For the diagnosis of GDM, the on-site values have been used. However, the glucose values 
analyzed at the hospital laboratory were used in cases of missing on-site values (FPG, n=4; 2-h 
PG, n=13), or values were extracted from the medical records (n= 2).  
The fasting and 2-h plasma glucose values, originally continuous variables, were categorized into 
a binary form (GDM and non-GDM) based on a defined cut-off level, e.g. 1999 WHO-criteria. 
This was the main outcome variable, in other words the disease or health-related variable being 
studied (Mosdol & Brunner, 2005).  
 
Vitamin D level 
A 25(OH)D test is a blood test to determine the level of 25-hydroxyvitamin D. The plasma 
concentration of vitamin D was analyzed from the same venous blood sample drawn for fasting 
glucose. Women with vitamin D values below predefined limits were advised to take supplements 
and letters were sent to the their GP’s.  
 
4.4.2.2 Anthropometric assessments  
Anthropometry involves the physical measurement of some or several aspects of human body 
size, and is relatively quick, simple and cheap to perform (Bates, Nelson, & Stanley, 2005).  
 
Height, weight, BMI and body fat 
Body height was measured to the nearest 0.1 cm with a fixed stadiometer. Height may serve as a 
proxy measure for early life socioeconomic factors, and stunting can be a marker of the nutritional 
status or living conditions during fetal and/or early life (Jenum et al., 2005; Ogonowski & 
Miazgowski, 2010). This variable was used with this intention in the regression analysis.  
 
Body weight and composition was measured with a Tanita-weight BC 418 MA body fat analyzer 
(Tanita Corp., Tokyo, Japan) in light clothing and without shoes. The values for body fat were 
available in kilograms (kg) and percent (%). A simpler version of this device is validated in 
pregnant women previously (Ueda et al., 2006). 
 
Body mass index (BMI) is the most commonly used measure of undernutrition and overnutrition 
in adults, and the easiest anthropometric measure of fatness (Bates et al., 2005). Pregnancy BMI 
was calculated as the maternal weight (in kilograms) divided by the square of height (in meters). 
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This variable, originally continuous, was later divided into three categories for certain analysis. 
The cut points for the categories were selected according to the WHO cut-off. 
 
In addition, recalled maternal pre-pregnancy weight was self-recorded to the nearest kilograms. 
However, this variable is not the primary focus of this study because of its inherent subjectivity 
and the absence of data for one city district. Pre-pregnant BMI was calculated as pre-pregnant 
weight/measured height2. 
 
4.5 Statistics  
After registration in Epidata, the data file was opened in SPSS version 20 (SPSS, Chicago, IL), 
where all analyses were carried out. Descriptive analyses were performed to obtain a description 
of the characteristics of the sample. To show differences between various ethnic groups, one-way 
ANOVA was performed for normally distributed continuous variables, and Pearson’s chi-square 
test for categorical variables. Mean and standard deviation (SD) are presented for continuous 
variables, in addition to median and interquartile ranges (IQR), and number and percentage are 
reported for categorical variables.  
 
For the main outcome variable (GDM), the differences in prevalence were tested for each ethnic 
group with the reference group (Norway & other Western) using a Pearson’ chi-square test.  
Independent sample t-test was performed to determine any differences in continuous variables 
(age, BMI) between the two groups of data (with GDM and without GDM), as well as the study 
cohort and the excluded subjects.  
 
To compare the prevalence rates from this study with the rates found in the STORK Groruddalen 
study, a Z-test for proportions has been used. This calculator is used to check whether there is a 
statistically significant difference between the observed results for the two independent groups, at 
the 95% confidence level.  
 
Logistic regression analyses were performed to identify the effect of ethnicity and other predictors 
on the categorical outcome of GDM. Prior to adding variables into the models, multicollinearity 
was checked for by requesting collinearity diagnostics, and variables were included and removed 
from the model accordingly. Additionally, Pearson correlations were performed to check high 
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intercorrelations among the predictor variables, and the highest correlation coefficient found was 
0.20.  
 
In model A ethnicity was added showing the effect of each ethnic group along with age and 
parity. Other predictive factors were added step-wise. In model B, BMI and first-degree relatives 
with diabetes were added. The final model, model C, included height, percentage body fat and 
gestational week, while BMI and parity were removed. Variables were retained in the model if 
they were significant in the presence of other covariates or were known to be biologically 
important (well-established risk factors). Nagelkerke R2 shows the explained variance of the 
model. Statistical significance level was set to P<0.05, and a 95% CI for the odds ratio (OR). 
 
4.6 Ethics  
Ethical considerations apply throughout and are integral components of the research process.  
This study entails personal health information, which, according to the Regional Committees for 
medical and health research ethics (REC) (2012) is defined as: “Confidential information in 
accordance with section 21 of the Healthcare Personnel Act and other information and 
assessments regarding health conditions or which is of significance to health conditions, which 
can be associated with an individual”.  
 
When conducting research on human biological material or personal health information, consent 
is the primary regulation rule. Informed consent is defined as “The process of agreeing to take part 
in a study based on access to all relevant and easily digestible information about what 
participation means, in particular, in terms of harms and benefits” (Parahoo, 2006, p. 469). In the 
current study, data was collected by midwifes on a routinely basis at the CHC’s, mainly for 
clinical use. The women attending for antenatal care were informed about the STORK 
Groruddalen study, of which the screening for GDM is a result. However, they have not been 
informed that their data will be analyzed as part of this master thesis. Hence, no written consent 
was signed prior to the study and the participants were not given the right to withdraw or restrict 
their data from analysis. 
 
In cases where personal health information has already been obtained without requesting consent, 
dispensation from professional secrecy requirements is necessary (REC, 2012). Based on the 
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degree of sufficient justification provided, REC provides advice on whether permission to access 
the requested confidential patient information should be given or not.  
 
For this study, REC for South Eastern Norway approved the study protocol with the no 415316. 
The personnel involved in the data collection and preparation were bound by an oath of 
confidentiality, as was I when receiving the data material. The data routinely collected were stored 
separately at the CHC’s and kept locked after collection. After receiving the data for this master 
thesis, data was stored at the University of Oslo, Department of General Practice at the office by 
Ullevål Hospital, and access was only possible from this place. The data were made anonymous 
after registration in Epidata, and confidentiality is preserved. There are no disclosures of 
information that may identify individuals.  
 
4.7 Funding  
There are no requested sources of expenses associated with this study. The improvement and 
strengthening of the routine antenatal care, consisting of universal screening with OGTT and 
measurement of vitamin D status, is supported by The Norwegian Directorate of Health and 
collaborative partners in the city of Oslo (Stovner, Grorud and Bjerke administrative districts).  
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5 Results  
5.1 Characteristics of the women  
Of the 1018 participants, valid data necessary to estimate the prevalence of GDM between 24 and 
34 weeks of gestation existed for 966 women (95%). Sixty-four percent were from an ethnic 
minority group, with the largest groups being composed of South Asians (24%) and Middle 
Easterners (16%). The study population, representing 73 different countries of birth, is categorized 
into seven ethnic groups and displayed in figure 2. Countries making up the categories, along with 
the numbers in each, are presented in table 2. Norway, Pakistan and Sri Lanka are the countries 
that contribute with most participants, with 334, 153 and 59 women, respectively. The group 
“South America”, consisting of only 16 women, is presented and included in the descriptive 
results, but will not be given emphasis or included in further regression analysis due to small 
sample size.  
 
!
 
Figure 2: Pie chart showing the total cohort stratified into 7 ethnic groups with percentages (%). 
 
 
 
Europe!&!Other!Western,!36%!East!Europe,!7%!South!Asia,!24%!East!Asia,!7%!Middle!East,!16%!SubQSaharan!Africa,!8%!South!America,!2%!
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Table 2 Ethnic origin of the study cohort, n=966. If less than 5 women have origin from a specific 
country, they are included in the group 'other'. 
 N % 
Total 966 100 
Europe & other Western 
Norway 
Sweden/Denmark/Finland 
Other Western Europe 
352 
334 
10 
9 
36 
95 
3 
2 
East Europe 
Poland 
Bosnia 
Kosovo 
Litauen 
Makedonia 
Romania 
Other Eastern Europe 
69 
19 
10 
6 
6 
6 
5 
17 
7 
28 
15 
9 
7 
9 
7 
25 
South Asia 
Pakistan 
Sri Lanka 
India/Bangladesh 
232 
153 
59 
20 
24 
66 
25 
9 
East Asia 
Philippines 
Vietnam 
Thailand 
Other East Asia  
65 
27 
22 
11 
5 
7 
41 
34 
17 
8 
Middle East 
Turkey  
Afghanistan 
Morocco 
Iraq 
Iran 
Palestine 
Other Middle East  
153 
34 
28 
27 
26 
15 
5 
19 
16 
22 
18 
18 
17 
10 
3 
11 
Sub-Saharan Africa 
Somalia 
Ethiopia 
Eritrea 
Ghana 
Other Sub-S. Africa  
78 
29 
18 
8 
5 
18 
8 
37 
23 
10 
6 
24 
South America 
Other South and Central America 
17 
17 
2 
100 
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Table 3 presents the baseline characteristics of the study population stratified into ethnic groups. 
The mean (S.D) maternal age at time of OGTT was 30.4 years (4.7), and the BMI was 27.5 kg/m2 
(4.2). The women from Norway and South America were the oldest, and had lower parity, while 
the Sub-Saharan Africans had the highest proportion of multiparous women (34.2%). East Asian 
subjects had the lowest BMI and Middle Eastern women the highest. The group with the highest 
proportion of relatives with diabetes was South America, followed by Middle East and South 
Asia. The fasting glucose level was lowest among women from East Asia (4.3 mmol/l (0.4)) and 
highest in women from South Asia (4.7 mmol/l (0.6)). On oral glucose tolerance testing, the 
groups Sub-Saharan Africa and ‘Norway and other Western’ had the lowest 2-h glucose levels. 
Norway had the highest levels of vitamin D while the Middle Eastern women had the lowest 
levels. Statistical significant differences between the ethnic groups were found for all parameters, 
and groups differing significantly from ‘Norway and other Western’ are marked with a footnote in 
the table.  
 
 
 
 
Table 3 Characteristics of the sample stratified into ethnic groups. Data are mean (S.D) and n (%) unless otherwise stated. 
 
 
N 
 
Total 
n=966 
Norway! 
n=362 (37) 
E. Europe 
n=71 (7) 
S. Asia  
n=238 (24) 
E. Asia 
n=66 (7) 
Mid. East  
n=158 (16) 
S-S. Africa 
n=78 (8) 
S. America 
n=18 (2) 
P 
Age (years) 966 30.4 (4.7) 31.3 (4.5) 29.8 (4.8) 29.6 (4.6)**1 31.0 (5.1) 29.8 (4.9)** 29.5 (4.2)** 31.8 (5.0) <0.001 
Gestational age (weeks) 966 28.6 (1.5) 28.7 (1.5) 28.3 (1.4) 28.3 (1.6)§§ 28.6 (1.3) 28.5 (1.4) 28.9 (1.8) 28.7 (1.3) 0.006 
Parity, n (%) 871                 <0.001 
    Nulliparous   396 (45.5) 181 (56.6) 28 (45.9) 75 (36.8) 27 (50) 55 (38.2) 21 (29.6) 9 (52.9)   
    Uniparous    310 (35.6) 117 (36.6) 25 (41.0) 68 (33.3) 17 (31.5) 50 (34.7) 27 (38.0) 6 (35.3)   
    Multiparous (≥ 2)   165 (18.9) 22 (6.9) 8 (13.1) 61 (29.9) 10 (18.5) 39 (27.1) 23 (34.2) 2 (11.8)   
BMI (kg/m2) 947 27.5 (4.2) 27.0 (3.9) 26.9 (3.7) 27.7 (4.0) 25.5 (2.5)$ 28.5 (4.1) 27.5 (3.8) 27.6 (2.1) 0.001 
BMI pre-pregnant (kg/m2)* 578 23.9 (3.8) 23.9 (3.9) 23.6 (3.8) 24.5 (4.2) 21.6 (2.0)** 24.5 (3.8) 24.2 (3.9) 24.3 (2.7) <0.001 
Height (cm) 963 163.7 (7.2) 168.2 (6.0) 166.9 (5.5) 159.9 (6.5)** 158.3 (5.6)** 161.7 (5.7)** 161.4 (6.2)** 160.4 (3.9)** <0.001 
Weight (kg) 954 73.9 (12.4) 77.7 (12.3) 76.2 (11.4) 70.8 (11.9)** 62.5 (7.5)** 74.2 (11.7)** 73.6 (11.9) 69.1 (8.1)** <0.001 
Body fat (percent)  947 37.4 (5.7) 36.9 (6.0) 36.7 (5.8) 38.5 (5.5)** 33.9 (4.4)** 37.5 (5.4) 40.1 (5.5)** 38.0 (4.6) <0.001 
Family with diabetes, n (%) 862 246 (29) 64 (20.2) 16 (25.0) 74 (35.9) 19 (35.2) 52 (38.0) 13 (19.1) 8 (50.0) <0.001 
Fasting glucose (mmol/l) 966 4.6 (0.6) 4.5 (0.5) 4.5 (0.5) 4.7 (0.6)** 4.3 (0.4) 4.6 (0.6) 4.6 (0.5) 4.6 (0.6) <0.001 
2-h glucose (mmol/l) 963 6.2 (1.4) 5.9 (1.3) 6.3 (1.2) 6.4 (1.5)** 6.4 (1.3) 6.4 (1.3)** 5.8 (1.3) 6.4 (1.2) <0.001 
Vitamin D (nmol/l)a 954 73 (49) 88 (45) 81 (42) 61.0 (46)** 71 (57)** 58 (42)** 54 (56)** 65 (43) <0.001 
Earlier GDM, n (%) 445 34 (7.6) 4 (3.1) 4 (12.9) 14 (11.6) 5 (18.5) 4 (4.9) 2 (4.3) 1 (12.5) 0.012 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*!Data$available$from$578$women$only$!
!Includes)Norway)&)other)Western!countries!Differences)are)tested)with)ANOVA)for)continious)variables)and)chi"square'for'categorical'variables.'!**P<0.001,'when'compared'with'women$from"Norway"&"other"Western,!$!P=0.001,'when'compared'with'women'from'Norway'&'other'Western,'§§"p=0.006,'when'compared)with)women#from#Norway#&#other#Western.!a"Median,(IQR!
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A comparison between women who were included in the study (n=996) and those 
excluded  (n=52) according to previously described criteria was also made (table 4). 
Among the women who participated and those who were excluded, the mean age and 
BMI was 30.4 years (4.7) and 27.5 kg/m2 (4.1) and 29.5 years (4.6) and 26.3 kg/m2 
(4.5), respectively. Baseline characteristics did not differ significantly between those 
included and excluded, except for gestational week at OGTT, as excepted. 
 
Table 4 Baseline characteristics of the study cohort and excluded subjects. Data are 
mean (SD) or n (%).  
! ! Study!sample!
!!!!!!!!!!n=966!
!!!!!!!!!!!Excluded!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!n=52!
P*!
! ! N! ! N! ! !
Age!(years)!
Gestational!age!(weeks)!
966!
966!
30.4!(4.7)!!
28.61!(1.5)!
51!
48!
29.5!(4.6)!!
26.87!(6.2)!
0.187!
<0.001!
Parity,!n!(%)!
!!!!Nullip.!!
!!!!Unip.!!
!!!!Multip!(>2)!
871! !
396!(45.5)!
310!(35.6)!
165!(18.9)!
40! !
15!(37.5)!
14!(35.0)!
11!(27.5)!
0.370!
Ethnic!origin,!n!(%)!
!!!!Norway!&!Other!W.!
!!!!NonDWestern!
966!! !!
352!(36.5)!
614!(63.6)!
51!! !
14!(27.5)!
37!(72.5)!
0.192!!
Family!with!diabetes,!n!(%)! 862! 246!(29)! 35! 12!(33)! 0.536!
BMI!(kg/m2)! 947! 27.5!(4.1)! 44! 26.3!(4.5)! 0.058!
PreLpregnant!weight!(kg/m2)! 578! 64.9!(11.7)! 22! 62!(16.1)! 0.288!
Fasting!glucose!(mmol/l)! 966! 4.65!(0.6)! 48! 4.69!(0.6)! 0.668!
Vitamin!D!(nmol/l)!
City!district,!n!(%)!
!!!Stovner!
!!!Grorud!
!!!Bjerke!
954!
966!
76.1!(36.9)!
!
356!(36.9)!
370!(38.3)!
240!(24.8)!
50!
52!
66.9!(36.1)!
!
26!(50.0)!
13!(25.0)!
13!(25.0)!
0.084!
0.101!
* p values from t-test and chi-square.  !
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5.2 Prevalence of GDM 
The number of women diagnosed as having GDM according to the WHO criteria was 132, 
giving a crude prevalence rate of 13.7 (95 CI: 11.5-15.8). The prevalence rates in the largest 
ethnic groups were 8.2% (95 CI: 5.3-11.0) in Western Europe, 20.3% (95 CI: 14.8-25.1) in 
South Asia and 19.0% (95 CI: 12.7-25.2) in Middle East (figure 3). The women from Sub-
Saharan Africa had the lowest prevalence at 7.7% (95 CI: 1.7-13.6). When each ethnic group 
was compared with the group ‘Norway & other Western’, statistical significant differences in 
the prevalence were found for South Asia (p<0.001) and Middle East (p=0.001), while East 
Asia was borderline significant (p=0.051).  
 
 
Figure 3: Crude GDM-prevalence, with 95% CI, according to the WHO-criteria, presented for 
the total cohort and 6 ethnic groups (South America not included due to small sample size).  
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5.2.1 Comparison with prevalence rates from STORK-Groruddalen study 
In STORK Groruddalen (Jenum et al., 2012) the study sample consisted 759 women with had 
valid data in gestational week 28. The number of women diagnosed with GDM was 99, 
giving a crude prevalence rate of 13.0% with the WHO-criteria. Despite finding a similar 
total prevalence for the STORK cohort and the women in this study, the rates found for some 
of the ethnic groups are slightly different in the two (figure 4). However, overlapping 
confidence intervals indicate that the findings from this study do not differ from STORK. The 
Western European had a prevalence of 11% in the latter, compared to 8% found in this study. 
Contrary, the South Asian women have prevalence of 20.3% in this study compared to 14.8% 
in STORK. The East Asian and Middle Eastern have slightly higher prevalence rates in this 
study as well, while the Eastern European had a twice as high prevalence at 17.0% in 
STORK, compared to 8.5% found in this study. Moreover, when comparing the proportions 
in pairs of groups, none of the prevalence estimates were statistically significant different 
from one another. The results for the women from Sub-Saharan Africa and South America 
have not been compared, as these groups were merged into one in STORK, and are presented 
separately in the current study.  
 
$
Figure 4: GDM-prevalence with 95% CI for the STORK Groruddalen study cohort and the 
current study sample, according to the WHO-criteria. Sub-Saharan Africa and South America 
are not presented due to different categories in STORK G.  
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5.3 Associations with GDM 
5.3.1 Differences between the GDM and non-GDM group 
The mean maternal BMI was significantly higher in women with GDM compared to women 
with normal glucose levels (table 5). Significant differences were also found when comparing 
ethnicity (p<0.001) and family history of diabetes (p<0.001). Body fat percentage (p=0.002), 
height (p<0.001) and vitamin D levels (p=0.035) were different between the non-diabetic 
group and the women who developed GDM as well. Age, parity, BMI pre-pregnancy and 
gestational age were not significantly different between the two groups.  
 
Table$5$Characteristics$of$the$GDM$and$non@GDM$group.$Values$are$expressed$as$mean$
(S.D)$and$n$(%).$$
    Non-GDM 
n=833 (86.3) 
GDM  
n=132 (13.7) 
     P + 
Age (years)  30.4 (4.7)  30.4 (4.6) 0.996 
Gestational age (weeks) 28.6 (1.43) 28.4 (2.14) 0.094 
Ethnicity, n (%)     <0.001 
  Norway & Western 323 (39) 29 (21)  
  East Europe 62 (7) 6 (5)  
  South Asia 185 (22) 47 (36)  
  East Asia 54 (6) 11 (8)  
  Middle East 124 (15) 29 (22)  
  Sub Saharan Africa 72 (8) 6 (5)  
  South America 13 (2) 4 (3)  
Parity, n (%)     0.192 
  Nulliparous 342 (46) 53 (44)  
  Uniparous 272 (36) 38 (31)  
  Multiparous (>2) 135 (18) 30 (25)  
BMI (kg/m2) 27.4 (4.1)  28.3 (4.1) 0.014 
BMI pre-pregnancy (kg/m2)* 23.9 (3.8) 24.4 (3.9) 0.232 
Weight (kg) 73.9 (12.5)  73.7 (11.3) 0.861 
Body Height (cm) 164.1 (7.3) 161.2 (6.5) <0.001 
Body Fat, (percentage) 37.2 (5.7) 38.9 (5.5) 0.002 
Family history of diabetes, n (%) 190 (26) 56 (48) <0.001 
Vitamin D (nmol/l) 77.1 (37.4) 69.6 (33.0) 0.035 *"Data"available"from"578"women"only!
+P values for the difference between the groups, tested with t-test and Pearson chi-square. 
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Figure 5 displays the prevalence of GDM calculated within three BMI classes, as defined by 
WHO: (1) normal: BMI <24.9 kg/m2; (2) overweight: BMI between 25 and 29.9 kg/m2; and 
(3) obese: BMI >30 kg/m2, further stratified by ethnic group. For two of the groups, the 
prevalence of GDM rises with increasing category of BMI; however, this is not the case for 
women of Middle Eastern origin, indicating that the association varies markedly by ethnic 
group. Further, a linear trend was only observed for the South Asians (p=0.041), for which 
the prevalence more than doubled from the normal class (15.9%) to the obese class (31.0%).  
 
!
Figure 5: The prevalence rates of GDM with 95-CI according to classes of maternal body mass 
index (kg/m2), shown for three ethnic groups. Statistical differences tested with Person chi-
square. 
 
At a BMI of >30 kg/m2, the prevalence of GDM was almost two times higher among Middle 
Eastern, and more than three times higher among South Asian women (18.0% and 31.0, 
respectively) compared with Norwegians (9.9%), a statistically significant difference 
(p=0.005). The ethnic groups differed significantly also at BMI 25-29.9 kg/m2 (p=0.008), but 
not at <24.9 kg/m2 (p=0.108). 
 
Similar associations were not found between maternal age and GDM, nor were any strong 
trends observed (figure 6). The age categories were as follows: (1) 26.9 years; (2) 27-32.9 
years; and (3) >30 years. The Western women had the highest prevalence of GDM in the 
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youngest age group, while the Middle Eastern had the highest rates in the oldest age group. 
For the South Asian women, the highest prevalence of GMD was found for the category 27-
32.9 years. The three groups differed significantly from each other in both the latter age 
group (p=0.001) as well as in the highest age group (p=0.013).  
 
!
Figure 6 The prevalence rates of GDM with 95-CI in the study population according to age-
groups, shown for three ethnic groups. Statistical differences tested with Person chi-square. 
 
 
5.3.2 Effect of ethnicity on GDM 
Logistic regression analyses were performed to assess the association of a number of factors 
on the development of GDM. The first column in table 6 presents univariate analysis for the 
variables. For GDM, ethnic origin from South Asia (OR: 2.66, CI: 1.54-4.59) and Middle 
East (OR: 2.42, CI: 1.34-4.37) was an independent factor, when adjusted only for age and 
parity (model A). After further adjustments for BMI and first-degree relatives with diabetes 
(model B), the observed associations were still present between these ethnic groups and the 
risk of GDM.  
 
In the final model (model C) parity and BMI were removed and replaced with body fat 
percent, height and gestational age at OGTT. As shown in the table, four of the independent 
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model (ethnicity, family history of diabetes, height and body fat percentage). Having a 
background from South Asia and first-degree relatives with diabetes were the strongest 
factors of GDM, both recording an OR of 2.18. This indicates that women from South Asia 
and Middle East are more than 2 times likely to develop GDM when compared to the 
reference category Norway and other Western, controlling for all other factors in the model. 
Likewise, having first-degree relatives with diabetes increases the likelihood of developing 
GDM more than 2 times. The model as a whole explained 11.7% (Nagelkerke R squared) of 
the variance in GDM status. 
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Figure'6'Multiple logistic regression models, showing the impact of ethnic origin on the categorical outcome of GDM after adjusting for covariates.'
!! !! Univariate) Model)A) Model)B) Model)C)
!!
!
OR!(95%!CI)! P! OR!(95%!CI)! P! OR!(95%!CI)! P! OR!(95%!CI)! P!
Age) !! 1.00!(0.9601.04)! 0.996! 0.99!(0.9401.04)! 0.867! !! 0.99!(0.9401.04)! 0.802! !! 1.00!(0.9601.05)! 0.699!
Ethnicity)) !! !! !! !! !! !! !! !! !! !!
!! Norway!&!Western!(ref.)! 1! !! 1! !! !! 1! !! !! 1! !!
!! East!Europe! 1.06!(0.4202.66)! 0.900! 0.72!(0.2402.15)! 0.563! !! 0.87!(0.2802.68)! 0.814! !! 1.28!(0.4903.36)! 0.606!
!! South!Asia! 2.83!(1.7204.65)! <0.001) 2.66!(1.5404.59)! <0.001) !! 2.85!(1.5605.20)! 0.001) !! 2.18!(1.1704.04)! 0.013)
!! East!Asia! 2.26!(1.0704.81)! 0.033) 2.04!(0.9004.61)! 0.087! !! 1.91!(0.7404.91)! 0.176! !! 1.50!(0.5603.95)! 0.411!
!! Middle!East! 2.60!(1.4904.53)! 0.001) 2.42!(1.3404.37)! 0.003) !! 2.26!(1.1704.35)! 0.014) !! 2.07!(1.0704.00)! 0.030)
!! Sub!Saharan!Africa! 0.98!(0.3702.31)! 0.873! 0.75!(0.2702.08)! 0.589! !! 0.98!(0.3402.82)! 0.987! !! 0.76!(0.2702.14)! 0.604!
Parrity) !! !! !! !! !! !! !! !! !! !!
)) Nulliparous!(ref.)! 1! !! 1! !! !! 1! !! !! !! !!
)) Uniparous! 0.90!(0.5701.41)! 0.658! 0.89!(0.5401.44)! 0.635! !! 0.92!(0.5501.55)! 0.766! !! !! !!
)) Multiparous!! 1.46!(0.8802.34)! 0.146! 1.14!(0.6302.06)! 0.645! !! 1.25!(0.6602.36)! 0.481! !! !! !!
BMI)(kg/m2)) 1.05!(1.0101.09)! 0.053! !! !! !! 1.03!(0.9801.08)! 0.165! !! !! !!
FirstFdegree)relatives)with)diabetes) 2.68!(1.8003.99)! <0.001) !! !! !! 2.39!(1.5403.72)! <0.001) !! 2.18!(1.4303.34)! <0.001)
Height)(cm)) 0.94!(0.9100.97)! <0.001) ! ! ! ! ! ! 0.96!(0.9300.99)! 0.045)
Gestational)week) 0.99!(0.9901.00)! 0.095! !! !! !! !! !! !! 1.00!(0.9901.00)! 0.886!
Body)fat)(%)) !! 1.05!(1.0101.08)! 0.003) !! !! !! !! !! !! 1.05!(1.0101.09)! 0.006)
Vitamin)D)(nmol/l)) 0.99!(0.9800.99)! 0.035) !! !! !! !! !! !! !! !!
PreFpregnant)BMI)(kg/m2))) 0.99!(0.9701.01)! 0.472! !! !! !!
!
!! !!
!
!!
Weight)(kg)) 0.99!(0.9801.01)! 0.861! !! !! !!
!
!! !!
!
!!
Nagelkerke)R2) !! !! 0.056) 0.110) 0.117)
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6 Discussion  
A discussion of the methodological considerations and the main findings in this study will be 
presented in this chapter.  
 
6.1 Methodological considerations 
When interpreting the results of a study, strengths and weaknesses of the methodology 
applied should be taken into account. This section aims to highlight, among other issues, 
possible effects of bias, the ethical aspect and the question of generalizability.  
 
6.1.1 Study design 
This study applies a cross-sectional design assessing the prevalence of GDM at a specific 
point in time, e.g. the scheduled check-up where universal screening for GDM is performed. 
Applying a cross-sectional design has several limitations as well as some advantages. A 
major advantage of this study is that the design makes it possible to collect information about 
many potential risk factors, and provides a broad base of knowledge about subjects who 
have/do not have the outcome of interest (Frigessi et al., 2006). In addition, such surveys 
provide useful information regarding the health status, behavior or trends of a population or 
specific group, which is essential for assessing the health needs and planning for appropriate 
health services (Yu & Tse, 2012). To this end, the current study may contribute to our 
knowledge about GDM, more precisely its frequency and potential risk factors, which is 
highly crucial information with importance for future development and improvement of 
antenatal care in Oslo.  
 
Cross-sectional studies are sometimes carried out to investigate associations between risk 
factors and the outcome of interest (Levin, 2006), although establishing cause-and-effect 
relationship between exposure and outcome is impossible (Frigessi et al., 2006). Because 
such studies are carried out at one time point, they do not give any indication of the sequence 
of events – whether exposure occurred before, after or during the onset of the disease 
outcome (Levin, 2006). In this study, a number of risk factors are found to be associated to 
the development of GDM. However, Information from before the actual pregnancy or from 
early gestation is lacking, making it difficult to infer causality between GDM and pre-
pregnancy factors. However, some exposures registered in this study, such as ethnicity, parity 
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and diabetes in family, are background factors independent of time; they are demographics 
characterizing the women. With BMI, on the other hand, which is shown to be associated 
with GDM (Chu et al., 2007), we cannot assume whether the high BMI existed before 
pregnancy, or is a result of the pregnancy. Worth to mention is also the fact that data on 
potential risk factors (age, parity, BMI etc.) were obtained before performing the OGTT. 
Neither the midwife nor the women knew the results of the blood tests at the point of data 
collection, implying that answers given are likely to be less influenced by the outcome of the 
screening. 
 
6.1.2 Bias and measurement error 
Errors are inevitable in almost any epidemiological studies, even in the best conducted 
research designs. When interpreting findings it is essential to consider carefully how much 
the observed association between an exposure and an outcome may have been affected by 
errors in the design, conduct and analysis (dos Santos, 1999). Bias refers to any trend in the 
collection, analysis or interpretation of data that can lead to results that are systematically 
different from the truth (Mosdol & Brunner, 2005). In this chapter, three broad categories of 
bias, selection bias, information bias and confounding will be discussed, in addition to 
measurement error.  
 
6.1.2.1 Selection bias 
Selection bias occurs when there is a difference between the characteristics of the people 
selected for the study and those who would be theoretically eligible but did not participate, 
and may result from using improper procedures for selection of subjects from the target 
population (dos Santos, 1999). In this study, two sources of potential selection bias should be 
considered. Estimating the number of theoretically eligible subjects e.g. all pregnant women 
living in the district, may be rater difficult as it requires a close monitoring of babies being 
born in the period and also taking in consideration women moving in and out of the area. Our 
best estimate indicate that about 70-80% of women living in these districts attended the CHC 
at least once during their pregnancy. Individuals with chronic diseases or medical conditions 
necessitating intensive specialist follow-up are unlikely to attend the CHC, and some also 
choose to visit private obstetricians. The first source of error would therefore be the exclusion 
from the study sample of those not attending the CHC’s. In that case, the prevalence of GDM 
might have been different among those included than among the population from which they 
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came from (Mosdol & Brunner, 2005). Our findings suggesting 13.7% GDM prevalence 
might be an underestimate if some women with high risk choose to see GP’s etc. instead of 
attending the CHC.  
 
Of those attending the CHC, a number of women were not offered the OGTT. The reasons 
for this are presented in the flowchart (figure 1); however, in contrast to STORK 
Groruddalen, we do not know exactly how many women should be classified into each 
category of not being invited. For instance, the number of women who had already been 
tested at their GP’s or arrived too late was not registered. In STORK, attendance at the CHC 
too late in pregnancy was the main reason for not being invited, constituting 81.7% of those 
not invited (Jenum et al, 2010). Practical challenges at the CHC also influenced the total 
number of invited women. As around 1-2 midwifes and only one laboratory personnel are 
responsible for screening at each CHC, women arriving during periods of sick leave or 
holidays are most likely not offered OGTT. Our best estimate, suggesting 77% participation 
of all invited, could therefore be subject to some uncertainty. Nevertheless, a participation 
rate of 77% is higher than in most studies today and is considered satisfying according to 
Johannessen et al. (2010), as it is above 50%.  
 
Furthermore, when some women (5%) were excluded from the analyses according to 
previously defined criteria, the scope of bias must be reassessed. Exclusion was done mainly 
on the basis of gestational week at point of screening and invalid OGTT data. However, upon 
analysis, baseline characteristics of subjects included and excluded did not differ 
significantly, except for gestational age, as expected (table 4).  
 
Gestational age at point of OGTT is commonly recommended between 24-28 weeks’. 
However, some women attend the CHC’s later or earlier than this. These women should 
ideally be excluded so that only women arriving in a set time between 24-28 weeks’ would 
constitute the study sample. In the current study, a less restrictive, but still medically 
acceptable criterion for inclusion of women attending was applied, e.g. between 24-32 
weeks’. Also, a few women with the GDM diagnosis were included despite arriving before 
these set criteria (at 20 weeks’) due to their risk profile. These women would probably have 
GDM at 28 weeks’ as well, and were included for this reason. Gestational week is always 
adjusted for in the multivariate statistical analyses. 
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The women attending the CHC’s for antenatal care have not been informed about the current 
study, as it was decided on later. Consequently, selection bias associated with recruitment is 
not an issue. If this group of women was invited to participate in this study, but only a subset 
was willing to take part, selection bias could be expected. This is because participants who 
volunteer to take part in such a study are likely to be more educated and health conscious 
(Mosdol & Brunner, 2005), or perhaps aware of their risk of GDM. Avoiding recruitment to 
this specific study probably has resulted in a larger number of women included, especially in 
some ethnic groups, compared to the STORK Groruddalen study (Jenum et al, 2012). 
Requesting written consent after obtaining data may introduce selection bias, as those willing 
to participate not necessarily represent the population of interest. This challenge is further 
explored in chapter 6.1.4 under ethical considerations. 
 
6.1.2.2 Information bias 
Information bias results from differences in the assessment of the exposure, outcome or other 
relevant variables, and occurs in the data collection stage of studies (Frigessi et al., 2006; 
Mosdol & Brunner, 2005). In this study, potential errors in measurement may be introduced 
by the observer or the instruments being used to perform the measurements.  
 
Interviewer-administrated questionnaire  
The questionnaires are filled out together with midwifes. Obtaining the information that the 
questionnaires were designed to seek requires that the women understand the questions being 
posed. Secondly it requires that the language in which the conversation takes place is fully 
understood by responders. Professional translators were used when needed in the STORK 
Groruddalen study (Jenum et al, 2010), and also in the current study. Nonetheless, there is a 
possibility that some questions might have been misunderstood or were not completely 
understood even though interpreters were in daily use. The use of interviewer-administrated 
questionnaires offers several advantages that could reduce such issues. For one, questions and 
responses can be clarified (WHO, 2008). The midwifes have the opportunity to explain 
complex or difficult questions with a simpler wording and may ensure that everything is 
completely understood. Moreover, such questionnaires are very useful if women visiting the 
CHC’s are less literate or illiterate, which there are cases of in Groruddalen. An additional 
strength of such questionnaires administered by an interviewer is fewer “blanks”, as the 
person posing the questions can make sure no fields are left unanswered (ibid.) However, this 
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advantage was not fully reflected in this study, as many variables were observed to have a 
high number of missing (table 3).  
 
Although questions are understood fully, conceptual matters, cultural relevance and the 
associations of words and phrases impact how an individual perceives it (Hunt & Bhopal, 
2004). This is of particular relevance for the question of first-degree relatives with diabetes. 
What is defined as a first-degree relative may differ across ethnic and cultural group. Some 
groups, for instance, South Asians could be defining cousins/uncles/aunts and extended 
family as first-degree relatives, while other, such as ethnic Norwegians, could be including 
only their close family, e.g. parents and siblings. A common understanding of this question is 
essential and requires that the interviewer explain whom to include in the term “first-degree 
relatives”. The Middle Eastern and South Asian group in this study have reported higher 
portions of relatives with diabetes (38% and 36%, respectively) compared to Norwegians 
(20%). One possible explanation for this could be that these groups have included extended 
family as well, which may affect the findings. On the other hand, there is also a possibility 
that these portions are even higher than reported considering that numerous individuals have 
unknown or undiagnosed diabetes (Jenum et al., 2005).  
 
Anthropometry and blood tests  
The major limitation of anthropometry is the extent to which measurement error can 
influence the interpretation of results. Achieving high levels of precision and accuracy is 
important and individuals performing the measurements should be given good training (Bates 
et al., 2005). During STORK, the study staff members were certified after extensive 
education, training courses, and on-site supervision (Jenum et al, 2010). Although not 
supervised in the current study, experienced midwifes are responsible for measuring height, 
weight and drawing blood. Also, if one person makes all the anthropometric assessments in a 
study, there is only within-observer measurement error to consider. However, the current 
study covers three CHC’S in different districts areas (Stovner, Grorud and Bjerke), requiring 
several anthropometrists over a period of nearly two year. This may add potential 
measurement errors (Bates et al, 2005). Intra- and inter-rater variability was assessed every 
sixth month in STORK, but this was not done in the current study conducted in a non-
research setting.   
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Furthermore, some measurement errors may have occurred when screening for GDM with 
the OGTT. As noted previously, a large number of women experienced nausea, resulting in 
vomiting. Although those who vomited before one hour passed were excluded, approximately 
8 women vomiting after one hour have been included. This could affect the 2-h plasma 
values obtained. Furthermore, at times the CHC staff experienced some difficulties when 
drawing blood in respect to finding the vein. As a result, it was decided to draw blood test in 
the finger instead. Such cases were not excluded and a lack of consistency in the 
measurement of glucose may consequently have occurred.   
 
6.1.2.3 Confounding bias 
A confounder is any factor that can cause or prevent the outcome of interest and at the same 
time is associated with the exposure in a way that it distorts the observed relationship 
between the two factors of interest (Mosdol & Brunner, 2005). An important question to 
consider in this study is whether the associations between GDM and observed risk factors can 
be due to a third variable associated to both the risk and outcome. Age is a common 
confounder in many studies since the risk of diseases usually increases with age. This risk 
factor could be confounding with both BMI and parity. In addition, the multifactorial cause 
of GDM may be determined by many conditions that are not known or were not measured in 
this study. An example is diet and physical activity, both of which could be potential 
cofounders of BMI. These risk factors were examined in STORK but information on them 
was not collected in the current study. Confounders can be controlled for in statistical models 
(Mosdol & Brunner, 2005), however it is not always clear whether a factor is confounding or 
not.  
 
6.1.3 Internal and external validity 
Internal validity is the degree to which the results of a study are correct for the sample of 
patients being studied. It is determined by how well the design, data collection, and analyses 
are carried out, and threatened by all of the biases discussed above (Fletcher, Fletcher, & 
Fletcher, 2012). The absence of such biases (selection, information and confounding bias) is 
essential for the external validity (Frigessi et al,, 2006). It refers to the degree to which the 
results of an observation hold true in other settings. Another term for external validity is 
generalizability (Fletcher et al., 2012), expressing the validity of assuming that women in this 
study are similar to other women. 
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As previously discussed, both in this study and in STORK (Jenum et al., 2010), the estimates 
based on data monitoring the activity at the CHC suggest that the majority of pregnant 
women living in the city districts attend the CHC for antenatal care. However, not all women 
prefer this option, and some probably choose to see their general practitioner or have all their 
follow-ups in specialist hospital care. For instance, women with known pre-gestational 
diabetes or those suffering from various conditions with potential impact on the pregnancy 
may need intensive follow-up by specialist already from the first trimester. These women are 
probably less likely to attend CHC’s for additional antenatal care. Thus, the study population 
could be considered representative only of healthy pregnant women in Groruddalen, as only 
these attend the CHC’s. There could also be cases of women visiting private obstetricians 
instead, however, there is little reason to believe that many would choose this option (Sletner, 
2014).  
 
The city districts in Groruddalen have a large proportion of the non-Western population in 
Norway (Statics Norway, 2014) and it can be assumed that women attending the CHC’s are 
representative for healthy women in reproductive age from the main ethnic groups living in 
the area (Jenum et al., 2010). Ethnic minority women are often underrepresented in most of 
the research projects, partly due to language and cultural barriers (Rooney et al., 2011). When 
participation is restricted to individuals with the ability to speak, read and understand 
Norwegian, several groups of particular interest for the study objectives may be lost. 
Moreover, inclusion of these groups was of great importance in this study, as the aim was to 
explore ethnic differences in the prevalence and risk factor of GDM. The CHC-setting has 
facilitated the inclusion of such hard to-reach groups in this study by collecting the data 
routinely and as a part of the standard care delivered to all women.  
 
6.1.4 Ethical considerations 
Research without consent is controversial, and some ethicists argue that it is almost never 
appropriate (Conaboy, 2013). In this study, access to personal health information without 
written consent, was given by the REC after presenting satisfying justification. The 
argumentation consisted of the three following conditions under which it is reasonable to 
conduct research involving access to personally identifiable data: (1) the proposed research is 
socially and publicly valuable; (2) obtaining consent would be practically impossible after 
data collection, or would likely bias the research; and (3) to minimize the intrusion of 
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privacy, strict safeguards for access are implemented and confidentially ensured (Miller, 
2008). In this chapter, an elaboration of this justification will follow.  
 
Observational research drawn from medical records, such as the current study, does not 
involve experimentation with human subject or any interaction between researchers and 
human subjects. Nothing is being done to or with the persons whose records are accessed, 
and there is no interference with their freedom or the course of their lives, especially since 
confidentiality of the data is protected (Miller, 2008). However, privacy is invaded by that the 
right to control access to private information, especially sensitive medical information 
obtained in the course of standard medical care, is taken away. 
 
To avoid such invasion of privacy, efforts could be made to contact the individuals involved 
prior to accessing their data for analysis. The women could be informed about the study and 
its purpose, and given the opportunity to opt-out of the research. However, seeking consent 
after data collection is quite challenging, especially in this particular study population. For 
one, participants have background from around 73 different countries, resulting in the need 
for consent forms in a large number of languages. Translating the consent forms and all 
relevant information in all these languages would be extremely time and resource consuming. 
Moreover, a significant number of women are illiterate making it rather impossible to explain 
the purpose of the study in a letter. 
 
Secondly, locating human subjects in order to obtain consent poses a well-known barrier, 
especially in large samples (Black, 2003). Many women move out of the area or change 
contact information. Others return to their countries of origin, or visit for longer or shorter 
periods. Individuals not responding are not assumed to be passively refusing consent, but 
rather being difficult to reach. When efforts are made to obtain informed consent, selection 
biases can be introduced into the data, as those who consent are not necessarily representative 
of the population of relevant patients (Miller, 2008). It is therefore likely that seeking consent 
after, rather than prior, to study enrolment may compromise the study’s scientific validity. 
 
Demonstration of an important public purpose for the research is of particular high value 
when taking use of private data without consent. Medical records can be a public resource for 
generating evidence relating to improving health care and population health (Miller, 2008). 
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However, it requires finding a balance between individual privacy and pubic goods, but by no 
means sacrificing the rights of individuals for the welfare of society. In this study, the 
potential for public benefit is thought to be high and the risk of harm to individuals low. As 
far as we know, only three CHC’s in Groruddalen have improved their antenatal care by 
offering screening for GDM to all pregnant women. This organizational change has been 
both resource-consuming and increased the workload for midwifes in the respective city 
districts. It is therefore essential that such changes are evaluated and their value assessed. If 
the findings of the current study suggest high prevalence of GDM, as reported in STORK 
(Jenum et al., 2012), screening for GDM should continue to be prioritized in these CHC’s, 
and should perhaps be offered in other parts of Oslo with high minority rates as well.  
 
Lastly, because these records contain sensitive personal information, mandating strict 
standards for protecting the private data from unwarranted use that can be harmful to 
individuals is ethically necessary (Miller, 2008). De-identifying of data as soon as possible 
after registering in Epidata is one of the steps taken to ensure privacy protections. In addition, 
when presenting the results, countries with less than 5 women are included in a group ‘other’. 
 
Harms and benefits for the women 
For women undergoing an OGTT, benefits apply in terms of identification of possible high 
glucose values. Information about the consequences of GDM for both mother and offspring 
was given, along with lifestyle advice aimed at preventing or treating the condition, mainly 
consisting of changes in diet and physical activity. The benefits of the screening are greater 
for those diagnosed with GDM, as the women likely wouldn’t be identified otherwise, or 
perhaps later in the pregnancy. Moreover, life style advice given may prevent future type 2-
diabetes in women and their children (Knowler et al., 2002), if followed post pregnancy as 
well.  
 
In has been suggested that screening for GDM can cause unnecessary anxiety for pregnant 
women (Hjelm, Berntorp, Frid, Aberg, & Apelqvist, 2008; National Institute for Health and 
Clinical Excellence, 2008). The OGTT is ideally offered between gestational weeks 24 to 28, 
at a point where most women no longer have nausea and vomiting associated with the first 
months of pregnancy. Nevertheless, a number of women experience hyperemesis when 
drinking the sweet glucose mix, and some end up vomiting as well. As previously noted, 
around 24 women (of which 16 were excluded) experienced vomiting in this study, making it 
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difficult to complete the test. However, a French study discovered that, overall, 97% of those 
screened judged the test to be acceptable, even though approximately half experienced nausea 
during testing and just under half found the test stressful (Gayet-Ageron et al., 2008).  
 
Other than these discomforts, no harms are associated with the OGTT. This study does not 
influence the women’s’ outcome and therefore confer no risk and no benefit to participants. 
 
6.1.5 Statistical methods  
When performing statistical analyses there is a possibility of reaching the wrong conclusion, 
as our results can be subject to two types of errors. The size of the sample is a large 
determinant of reporting false-negative findings, also called type II error e.g. believing that 
the groups do not differ when in fact they do (Pallant, 2010). A large study sample is one of 
the strengths in this study, as larger samples are expected to give more reliable results and 
have the advantage of greater statistical power (Nayak, 2010). Although the probability of 
type II error is reduced by including 966 women, some of the groups compared are quite 
small, in particular South America (table 3). This ethnic group was included in the ANOVA 
analysis of variance, but not in other analyses for this reason. For the comparison of 
prevalence with rates from STORK, two of the groups, Sub-Saharan Africa and South-
America, could not be compared due to these groups being merged into one in STORK. The 
same categorizing could have been made in the current study, making the comparison of 
these groups possible. However, this was recognized at a late point and therefore not done. 
 
Further, the risk for the second type of error is high in this study and should be considered 
carefully when interpreting the findings. Type I error refers to the possibility of finding a 
difference between groups when one does not actually exist (Pallant, 2010). For instance, one 
might conclude that there is a difference between the seven ethnic groups included for several 
variables, when in fact, there isn’t. Moreover, with large samples even small differences 
between groups may become statistically significant. Thus, one should be aware that such 
differences not always have any practical or theoretical significance (Pallant, 2010). In this 
study, the differences found in, for instance, age, BMI or glucose levels, between groups are 
not necessarily big or meaningful.   
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To reduce the probability of type I error and minimize the possibility that the variation 
observed is due to chance, the level of statistical significance could have been reduced to 1%. 
However, as many of the differences observed are highly significant (p<0.001) similar results 
would probably be obtained with a more stringent alpha level as well. In addition, post-hoc 
comparisons are designed to guard against the possibility of an increased type I error due to 
the large number of different comparisons being made (Pallant, 2010).   
 
For the risk factors identified with the multiple regression analysis, large increases in the 
OR’s are observed, for instance a doubled risk of GDM for certain ethnic origins. This 
indicates that the differences are large and important. Formal tests of interactions were not 
performed before performing the regression analysis, which should ideally be done as an 
essential step and prerequisite for these types of analyses; however, simple descriptive 
analyses did not indicate interaction.  !
In this study, several variables such as age, BMI, body fat etc. are presented as continuous 
variables in the descriptive statistics. Similarly, they were not categorized for the regression 
analyses. These variables could have been recoded into categorical forms, so that the 
distribution of data could be clearer. Height in particular could be interesting to explore, as 
there are obvious differences in the classes tall and short, according to ethnic origin.  
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6.2 Discussion of the main findings  
To our knowledge, this is the first study in Europe in a multiethnic population of healthy 
pregnant women, where the prevalence rates and risk factors for gestational mellitus diabetes 
are measured by universal screening offered as part of the routine care, outside a research 
setting. In the following chapters, the results from this study will be discussed and viewed in 
light of previous research in the field.  
 
6.2.1 Prevalence 
In this multiethnic population of women undergoing universal screening with OGTT, overall 
13.7% were found to have GDM, and the prevalence varied by ethnic group. South Asia was 
the group with highest prevalence, followed closely by women from Middle East. Significant 
differences in the prevalence rates were also found for these groups when compared with 
Norwegian women. Our results are consistent with other studies reporting high prevalence of 
GDM and T2DM in immigrants from these ethnic groups (Hedderson et al., 2012; Jiwani et 
al., 2012). In contrast, African women and ethnic Norwegians had the lowest prevalence. 
Similarly, Hedderson et al. (2010) found the lowest prevalence of GDM among white (non-
Hispanic) women and blacks when comparing 11 race-ethnicity groups in the US.  
 
As previously noted, comparing prevalence rates from other studies is difficult as there is no 
international consensus regarding the screening procedure for GDM (Buckley et al., 2012; 
Jiwani et al., 2012; Vandorsten et al., 2013). In Norway, the prevalence has not been assessed 
in a population-based cross sectional study before STORK, and representative data regarding 
rates of GDM in the total population are not available. The Medical Birth Registry of Norway 
from 2007 reported a total incidence of 1.3%, a number ten times lower compared with 
findings from this study (Norwegian Institute of Public Health, 2007). Other studies from 
comparable populations found lower rates as well (Galtier, 2010), while a Finnish registry 
data study reported a GDM-prevalence of 10-11% (Lamberg et al, 2012). Observed 
differences in the prevalence rates could be attributed to trends in age and BMI of the study 
population (Flack, Ross, Ho, & McElduff, 2010), and numbers are probably hampered by 
unsystematic screening and underreporting. In addition, the current study includes women 
with ethnic minority background, which in most cases increases the total prevalence found. 
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Comparing the results with findings from the STORK Groruddalen study is more relevant as 
the methods and criteria (WHO 1999) applied are identical. However, some differences in 
demographics, e.g. BMI, age and other relevant parameters, for the two study populations 
may exist. Although not significant, observed differences in GDM prevalence rates for some 
ethnic groups in the current study compared to STORK could be explained by the variation in 
countries of origin for several ethnic groups. For instance, fewer women from Somalia 
participated in this study compared to STORK (37% and 65%, respectively), and a larger 
proportion of individuals are included from Poland (28% and 16%, respectively) (Mørkrid, 
2013).  
 
6.2.2 Associations of ethnicity and other risk factors 
When controlled for maternal age and parity, ethnic minority background from South Asia 
and Middle East was significantly associated with GDM. These associations persisted after 
further adjustments for BMI and first-degree relatives with diabetes. Multiparity is suggested 
as a risk factor but findings are inconsistent as the relationship between parity and GDM is 
closely linked to two potential confounding factors, age and BMI (Dode & Dos Santos, 2009; 
Galtier, 2010). As women from ethnic minority groups were more likely to be multiparous 
compared to Norway and other Westerns, parity was included in the regression analysis in 
this study. However, this factor was non-significant in both model A and B, and parity was 
therefore not included in model C.  
 
BMI was also removed in the final model and replaced by body fat, as significant 
associations with GDM were not apparent. However, when assessing the prevalence of GDM 
according to BMI classes, a trend was observed indicating increasing prevalence rates with 
increasing BMI (figure 5). This was not observed in the Middle Eastern group for which the 
highest prevalence was found in the overweight class (BMI 25-29.9 kg/m2). Also, for each 
BMI class, the ethnic minority groups were more susceptible for GDM compared with the 
group Norway & other western.  
 
Furthermore, even at the lowest BMI cut point (<24.9 kg/m2), all groups showed high rates of 
GDM, suggesting that the disorder not only affect overweight and obese subjects, but also 
women with normal weight. The prevalence was especially high (15.9%) in the lowest BMI 
category for the South Asians in particular. This is in line with other studies reporting that 
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women from South Asia develop GDM at younger ages and lower BMI compared with other 
groups (Makgoba, Savvidou, & Steer, 2012). Hedderson et al. (2012) also found that the risk 
for GDM is high even at relatively low BMI cut-offs in Asian women.  
 
The reasons for a higher risk of GDM found at a lower BMI for Asians have been discussed 
but are still unclear. Ethnic differences in the percentage total body fat per BMI unit are 
reported in many studies (Deurenberg, Deurenberg-Yap, & Guricci, 2002; A. Misra & 
Khurana, 2011; Yajnik & Ganpule-Rao, 2010) and it has been concluded that Asians 
generally have a higher percentage body fat and more visceral adipose tissue compared with 
other ethnic groups (Lear, Humphries, Kohli, & Birmingham, 2007; Wulan, Westerterp, & 
Plasqui, 2010). This has led to a growing debate about the definition of overweight and 
obesity in Asian population, and the WHO proposed a different cut-off for these BMI 
categories (WHO Expert Consultation, 2004). Instead of classifying overweight at 25 kg/m2, 
the new cut-off suggests 23.0 kg/m2 for Asian populations. These cut-off values, which have 
not been applied in this study, would most likely have revealed other findings.   
 
Advanced maternal age is another well-recognized risk factor for GDM (Dode & Santos, 
2009). In this study, however, increasing age did not necessarily lead to higher rates of GDM 
(figure 6). This was further confirmed in the regression analysis, where age was not 
significantly associated with GDM. When comparing the Middle Eastern, South Asian and 
Western women, the latter ethnic group showed the highest prevalence in the lowest age 
category of <26.9 years. The rates for this age category were high also in the other groups 
(18.8 and 18.3, respectively), implying that a number of women develop GDM in a young 
age. It is however, not clear whether these young individuals with GDM are obese or 
overweight, as additional analyses adjusting for both BMI and age at the same time were not 
performed. 
 
The national guidelines in Norway recommend selective screening of GDM for women 
belonging in a high-risk group, where two of the criteria are age >38 years and BMI >30 
kg/m2 (Directorate for Health and Social Affairs, 2009). The findings from this study indicate 
that screening of women based on these risk factors could lead to a number of women not 
being identified, as many have GDM even in the absence of obesity and older age. Thus, the 
potential for missing a significant proportion of GDM cases following such recommendations 
for selective testing is high. In addition, these guidelines suggest considering the woman’s 
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ethnic origin when determining her risk for GDM and the need for screening. Contrary to age 
and BMI, our findings support the importance of this risk factor, as ethnic origin from both 
South Asia and Middle East were found to be associated with GDM. 
  
Height and gestational week at inclusion were also added to model C. In contrast to the 
STORK study, information on socioeconomic factors, such as educational level or 
employment, was not registered in the current study. Body height, however, may be used as a 
proxy for socioeconomic determinants related to stunting, and gives essential information on 
the mother’s nutritional status or living conditions during fetal and/or early life (Jenum et al., 
2005; Ogonowski & Miazgowski, 2010). For this purpose, height was included in the final 
model. An inverse association between height and GDM was found in this study, suggesting, 
in line with others (Galtier, 2010; Jenum et al., 2012; Kew et al., 2010; Ogonowski & 
Miazgowski, 2010) that low adult height is associated with GDM.  
 
A number of studies have suggested ethnic origin from South Asia and Middle East as a risk 
factor for GDM (Hedderson et al., 2010) but findings are inconsistent (Dode & Dos Santos, 
2009). Although still significant, the increased OR for women from South Asia and Middle 
East were reduced in the final model after additional adjustment for height and body fat. 
Similar findings were reported in the STORK Groruddalen study (Jenum et al., 2012) where 
the OR decreased for both of these groups and were no longer significant after adding early 
life SEP (height and education) to the model. Addressing this issue, Link & McKinlay (2009) 
showed that socioeconomic status is more important in determining diabetes rather than 
race/ethnicity, reinforcing findings from a number of other studies (Connolly, Unwin, 
Sherriff, Bilous, & Kelly, 2000; Cunningham et al., 2008; Rabi et al., 2006). 
 
Family history of diabetes, a well-documented risk factor for GDM (Galtier et al, 2010; Dode 
& Dos Santos, 2009), remained highly significant even in the fully adjusted regression 
model. As vitamin D status showed statistically significant OR for GDM in the univariate 
analysis, this factor was added to a fourth model. The estimates were unchanged in this 
model, and vitamin D status was not statistically significant when controlled for the other 
covariates (data not shown).  
 
In STORK (Jenum et al, 2012) other factors than those found in the current study were 
significant in the fully adjusted model, one being maternal age, which was not significant 
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even in the unadjusted analyses in this study. Parity was also significant contradictory to our 
findings. However, it should be noted that parity was categorized differently in the regression 
analysis in STORK, as parous (≥1), compared to three categories in this study. Additionally, 
the model contained pre-pregnancy BMI as compared to the current study where maternal 
BMI or percentage body fat has been used. Although shown in the univariate analyses, pre-
pregnancy BMI was not included in the models as data were lacking for one city district. The 
main difference is, however, that ethnic origin was not found to have an impact on GDM 
when controlled for other covariates in STORK. While ethnic origin from South Asia and 
Middle East showed increased OR in the current study, these OR would most likely be 
reduced when adding the variable education to the model, as was done in STORK.  
 
The R2 for the fully adjusted model, including both potentially modifiable risk factors and the 
non-modifiable risk factors, found that they together explain only 11.7 percent of the 
variation in GDM status. The large proportion (88.3%) of unexplained variation indicates that 
other factors associated with GDM remain to be identified or should have been included in 
the models. Factors that could have an impact are physical activity, diet and socioeconomic 
factors such as educational level, employment and the woman’s proficiency in Norwegian. 
Similarly, information on how long the women had been living in Norway and on the degree 
of acculturation could also have been recorded, both of which may influence the risk of GDM 
(Hedderson et al, 2010).  
 
6.3 Strengths & limitations  
A major strength of this study is the CHC setting in which universal screening is offered as 
an integrated part of the routinely antenatal consultations. This allows for a high inclusion 
rate when assessing the prevalence of GDM. Most women accepted to perform the OGTT 
and appreciated the opportunity to check for this condition that could affect their pregnancy 
and offspring. As all patients have been given this possibility, selection bias is likely to be 
reduced. In STORK Groruddalen, several ethnic groups were small, and the numbers have 
been increased in most groups in this study. 
 
This study also had some limitations. We lacked data on several potential confounding 
factors, including physical activity and diet. The observational design of this study makes it 
impossible to conclude that GDM is causally related to the risk factors observed; however, 
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such a relationship is plausible. Finally, It should be recognized that though larger than in the 
Groruddalen study, some ethnic groups were still relatively small. Because of limited 
numbers, we were unable to examine associations separately among subgroups of the sample 
(for instance for Somali women). The broad categorization of some ethnic groups will in 
addition fail to address differences that may exist within the same group, e.g. the Middle 
Eastern group, comprising a wide range of countries. The anthropometry as well as metabolic 
profile of women from, for example, Afghanistan may differ from that of women with 
Turkish origin.  
 
6.4 Implications for public health  
The results from this study show high prevalence of GDM, and the rates are higher among 
some ethnic groups compared to Norwegians. With the increasing prevalence of obesity, one 
can expect further rise in the rates of GDM in the coming years, especially in conjunction 
with a multiethnic population and advancing maternal age in Norway. This has important 
implications for public health policy. As maternal glucose increased, there is a higher 
expected rate of caesarean section, preeclampsia, large for gestational age babies and 
neonatal hypoglycemia (Hapo Study Cooperative Research Group et al., 2008). This will in 
turn have significant impacts on clinical workload and require additional resource allocation 
(Sweeting, Rudland, & Ross, 2013). Additionally, GDM requires care during pregnancy as 
well as continued care in the long term and follow up.  
 
As women have repeated contact with the health system during pregnancy, this period 
provides health professionals with a unique opportunity to provide education and to 
encourage healthy dietary habits and increased physical activity (Metzger et al., 2007). The 
CHC’s in Groruddalen and midwifes play a crucial role in early identification of GDM and 
pre-existing diabetes by offering universal screening as part of the routine care. Furthermore, 
as GDM is considered a risk factor for T2DM (Landon & Gabbe, 2011; Pedersen, 1971), its 
diagnosis provides an invaluable opportunity to highlight women at risk of future diabetes. 
This enables general practitioners in addition to midwifes, to engage in targeted monitoring 
and early life style intervention in the post-partum period as well (Sweeting et al., 2013). 
Given the strong evidence showing that lifestyle changes can prevent or delay the progression 
of T2DM in women with previous GDM (Knowler et al., 2002), this intervention opportunity 
should be embraced.  
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Moreover, it is of particular importance to identify women with impaired glucose tolerance 
and GDM at an early stage, so that appropriate treatment can be initiated to prevent adverse 
outcomes. Undiagnosed or poorly managed diabetes or hyperglycemia during pregnancy is 
associated with a higher risk of maternal and perinatal morbidity and mortality as well as 
poor pregnancy outcomes (World Diabetes Foundation [WDF] & Global Alliance for 
Women’s Health [GAWH], 2008). However, by screening patients merely on the basis of 
risk factors, one may not be able to detect all women with GDM, affecting the number of 
women who are not given the diagnosis and hence do not proceed to treatment. Several 
studies have confirmed that risk factor-based screening fails to identify some women with 
GDM (Anderberg, Kallen, Berntorp, Frid, & Aberg, 2007; Baliutaviciene, Petrenko, & 
Zalinkevicius, 2002; Minsart, Lescrainier, & Vokaer, 2009). This may have major 
consequences for public health, as allowing hyperglycemia in pregnancy may maintain a 
“vicious cycle” by increasing the risk of obesity, impaired glucose tolerance and diabetes in 
later generations (Castorino & Jovanovic, 2011). 
 
An accurate diagnosis of pregnant women with GDM, on the other hand, offers the 
possibility to decrease such conditions in future generations. There is also potential for 
intergenerational prevention of several other chronic diseases such as arterial hypertension, 
cardiovascular disease and stroke. Thus, one high-quality intervention related to maternal 
health service as universal screening for GDM, makes it possible to achieve several 
objectives with far reaching health and economic benefits (WDF & GAWH, 2008). Referring 
to the growing crisis of obesity and T2DM in both young and adult populations – a rapidly 
increasing portion of the global disease burden - Castorino and Jovanovic (2011) emphasized 
that failing to identify women with GDM and hence allowing hyperglycemia would be 
“adding fuel to the fire”. Yet, current guidelines (The Directorate for Health and Social 
Affairs, 2009) recommend selective screening, shown to score poorly in predicting GDM, 
perhaps due to economic and health system workload reasons. There is, however, not an 
agreement on which screening approach is optimal, as there is evidence pointing in favor of 
both selective and universal screening in the scientific literature. For instance, a large Danish 
study of over 5000 women reported that screening based on risk factors was as effective as 
universal screening (Jensen et al., 2003).  
 
With universal screening as part of the routine care one can expect an increase in the number 
of women diagnosed with GDM. The most obvious consequence of these additional 
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diagnoses is related to the health care cost and such financial implications clearly need 
serious consideration. In addition, the “medicalization” of pregnancy is also of concern, as a 
diagnosis of GDM may include labeling or treating women with mild gestational glucose 
intolerance with increased interventions and more intensive surveillance during pregnancy 
(Moses, 2010). 
 
As GDM is increasing with the increasing burden of obesity in women, its prevention 
depends on the prevention of obesity among young women of reproductive age. Prevention 
strategies should therefore focus on education on healthy diets and harms of obesity. Also, as 
mounting evidence supports a relation between growth and development during fetal and 
early life and health in later years, investment in the health and education of young women 
regarding their responsibilities during pregnancy and parenthood is of fundamental 
importance (Gluckman et al., 2008). Hence, a life-course perspective, in addition to a 
lifestyle perspective, should be promoted in any approach to health care. Moreover, 
awareness-raising among public, patients and providers about the risk of GDM as well as 
advocacy and training, are needed to prevent or reduce GDM in the population. Also, the 
results from many studies suggest that socioeconomic factors matter, perhaps more than 
ethnic origin per se. Interventions to prevent the onset of diabetes should therefore be focused 
even more on groups with low socioeconomic status.  
 
Future research  
Public health initiatives to address diabetes in pregnancy, such as universal screening for 
GDM, can be integrated into existing routines for antenatal care, as demonstrated by the 
CHC’s in Groruddalen. Such programs may be initiated more widely, for instance in other 
parts of Oslo, either in CHC’s or other antenatal services. However, economic implications 
related to the implementation of universal screening need to be taken into account. Future 
studies should therefore focus on the cost effectiveness and benefit of detecting and treating 
GDM, which has been questioned by those who are skeptical to universal screening in routine 
care. The national guidelines recommend selective screening as per today, and a change in 
these guidelines in favor of universal screening for all pregnant women along with its 
implementation will most likely result in increased health system workload.  
 
Prior to suggesting such major structural changes in the antenatal care in Norway, there is a 
need to estimate resources needed, in addition to advantages and limitations of this initiative 
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for the three city districts in Groruddalen where this had been integrated in the routine. Cost 
effectiveness analyses of the economic impact of implementing universal screening could 
give several answers. This may help consider whether universal screening of GDM and its 
management is cost-effective and should be added to the standard antenatal care package.  
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7 Conclusion  
The overall prevalence of GDM found in a multiethnic population in Groruddalen (Stovner, 
Grorud and Bjerke city districts) was 13.7%, and large differences were observed for the 
main ethnic groups. The highest prevalence rates were found for the women from South Asia 
and Middle East, while the lowest were found for women from Norway and other Western 
countries. This study further indicates that ethnic origin from South Asia and Middle East, 
first-degree relatives with diabetes, lower height and higher percentage body fat are 
associated with increased GDM risk. Such risk factors could help identify women with higher 
risk of GDM; however our findings suggest that women without some of these risk factors 
(older and overweight/obese) may develop GDM as well.  
 
The prevalence rates found in this study where OGTT was offered as part of the routine care 
are in line with the prevalence reported in the STORK Groruddalen research program. Our 
findings seem to justify universal screening as an integrated part of the antenatal care in this 
area with large proportions of ethnic minorities. Nevertheless, the benefit of detecting and 
treating GDM through standard routine care should be assessed in future studies.  
 
!
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